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Respiratory complications are life threating in Amyotrophic Lateral Sclerosis (ALS), 
and a proactive preventive approach is a key element in disease management. Non-
invasive ventilatory support and mechanically assisted cough are mainstay 
therapeutic techniques. Mechanical insufflation–exsufflation (MI-E) is an efficient 
tool used to improve cough in most patients with neuromuscular disorders, but the 
method often fails in ALS, especially when bulbar involvement is present. 
We do not fully understand why bulbar ALS patients do not seem to benefit from MI-
E, and thus we do not have evidence based guidelines to advise how treatment can be 
modified to be clinically more acceptable and efficient. Although the upper airways 
have been a suggested cause of this treatment failure, comprehensive studies of the 
laryngeal response patterns to MI-E have not been previously reported.  
Clinical respiratory physiotherapy and non-invasive ventilatory support is of vital 
importance to maintain respiratory health and quality of life in ALS, and it is 
therefore imperative that we gain more knowledge on how we can overcome the 
obstacles preventing MI-E from being effective in these patients.  
Thus, the overarching aim of this thesis is to investigate if and in what way abnormal 
laryngeal responses can possibly explain the frequently experienced lack of clinical 




1.1 Scientific environment  
The thesis originated from the PhD program of the Department of Clinical Science, 
Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway. 
The Western Norway Regional Health Authority and Norwegian National Advisory 
Unit on Long-term Mechanical Ventilation, Thoracic Department, Haukeland 
University Hospital have funded the study. 
The present study was carried out between 2011 and 2017 in collaboration with 
Norwegian National Advisory Unit on Long-term Mechanical Ventilation at Thoracic 
Department, Departments of Neurology, Otolaryngology, Pediatrics, Physiotherapy 
and Clinical Engineering at Haukeland University Hospital, Bergen, Norway and The 
Faculty of Health and Social Sciences, Western Norway University of Applied 
Sciences, Bergen, Norway. 
The main research environment was the WestPaed Research Group at Haukeland 
University Hospital. Collaborative research environments were Norwegian National 
Advisory Unit on Long-term Mechanical Ventilation and The Bergen Respiratory 
Research Group. 
 
The supervisors during this work have been: 
Ola Drange Røksund, physiotherapist, professor at the Faculty of Health and Social 
Sciences, Western Norway University of Applied Sciences, Bergen, Norway. 
Thomas Halvorsen, pediatrician, professor at Department of Clinical Science, Faculty 
of Medicine, University of Bergen, Bergen, Norway. 
John-Helge Heimdal, otolaryngologist, professor at Department of Clinical Medicine, 
Faculty of Medicine, University of Bergen, Bergen, Norway. 
Ole-Bjørn Tysnes, neurologist, professor at Department of Clinical Medicine, Faculty 
of Medicine, University of Bergen, Bergen, Norway. 
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Maria Vollsæter, pediatrician, PhD, senior consultant at the Norwegian National 
Advisory Unit on Long-term Mechanical Ventilation and Department of Pediatrics, 
Haukeland University Hospital, Bergen, Norway. 
 
Ove Fondenes, pulmonologist and the head of the Norwegian National Advisory Unit 
on Long-term Mechanical Ventilation, Haukeland University Hospital, Bergen, has 
served as a professional specialist and supervisor in relation to respiratory challenges 
and mechanical ventilation of patients with Amyotrophic Lateral Sclerosis. 
 
Statistical longitudinal analyses were carried out under the supervision of: 
Roy Miodini Nilsen, biostatistician, associate professor at the Faculty of Health and 







As a respiratory physiotherapist I am passionate about working with people with ALS 
and other neuromuscular disorders. The opportunity to contribute to the development 
of this field is a dream come true. My years as a PhD fellow have been fantastic and I 
aim to continue with further research. There are many people who contributed to my 
work and gave me support, and I want express my deepest gratitude.  
First, I am grateful to all the patients, their families and caregivers, and the healthy 
controls that participated in the study; I have learned so much from you! Without 
your contributions and patience, this work would not have been possible. 
Most of all, I want to thank my main supervisor Ola Drange Røksund. Your work 
with Exercise Induced Laryngeal Obstruction (EILO) inspired me to use your method 
and perform this study. Since I shared my idea with you, you have opened doors for 
me, including inviting me to join the WestPaed Research Group. Through the years 
you have kindly guided me with your enthusiasm, wisdom, knowledge and calmness. 
You have been my outstanding assistant in most of the laryngoscopy examinations, 
which is incredible! You are a good person and your support has been phenomenal, 
Thank you so much! I hope we can continue our cooperation in the future. 
Thomas Halvorsen, you are one of the smartest people I know. Thank you, especially 
for being there for me during the designing of the project and throughout the writing 
processes; I have learned so much from you and I truly admire your endless 
wondering and eagerness to understand everything!  
Thank you John-Helge Heimdal for all the discussions we have had during these 
years and the time you have used to provide me with a deep understanding of the 
larynx and its function. I have learned a lot from you and I will miss our 
conversations (which I always found to end too soon!).  
Ole-Bjørn Tysnes, you have been my cornerstone to understanding neurology. Thank 
you for all the neurological evaluations you performed, and for sharing your 
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knowledge and all the enthusiastic discussions we have had trying to understand the 
pathophysiology of our findings.  
Maria Vollsæter, thank you for being my co-supervisor during the last part of my 
PhD period and before that my research fellow and my colleague in the Norwegian 
Advisory Unit for Home Mechanical Ventilation (NKH); your brain is huge and your 
heart is even bigger. I am looking forward to our further working together, both 
clinically and in research. 
Ove Fondenes, you have been my mentor and advisor since 2002 when you hired me 
as respiratory physiotherapist in NKH. I have so much to thank you for; for all the 
opportunities my work has given me, your endless belief in me and the freedom you 
have given me through the years which has pushed me to do my best work. We still 
have a lot to do together and I am looking forward to all the new adventures with you 
and rest of our team in NKH. 
I am grateful to The Western Norway Regional Health Authority and NKH who have 
funded this study. I also want to thank the Thoracic department, and its head Kahtan 
Al-Azawy; and the Department of Physiotherapy, and head Else Sterndorff and my 
nearest leaders there Grete Ege and Theresa Johannessen, for allowing me to perform 
this study. 
Ola, Thomas and John-Helge, in addition to developing this research field you have 
also created a unique research environment with positive, supportive and a highly 
inclusive atmosphere. You are good at linking researchers in positive collaborations, 
and have a genius for teambuilding. I am very grateful to be part of this group and I 
want to thank the whole group for your support. I am especially in great gratitude to 
Astrid Sandnes, Maria Vollsæter, Hege Clemm, Magnus Hilland and Lorenz Sandven 
for performing the laryngoscopies and to Thor-Andre (Tollis) Engelsen for editing 
the film clips and helping me with illustrations. Thank you so much! Also our funny 
Englishman Zoe Fretheim- Kelly, thank you for your friendly help with the proofing 
of my thesis. 
Marit Renså and Gunvor Mo Norstein; our eminent nurses at the ALS outpatient 




examinations possible. Your help was outstanding! Neurologist Tiina Rekand, thank 
you for contributing the neurological examinations of several study participants.  
Anne-Kristine Brekka, thank you for your valuable help in Study #II, and thanks to 
statistician Roy Miodini Nilsen for your friendly guidance with statistical 
interpretation of the longitudinal data in Study #III. Liv Heide Magnusson, thank you 
for always being so positive when I needed help with scientific methods. 
My very good friends and truly inspiring colleagues Brit Hov, Michel Toussaint, 
Malin Nygren-Bonnier and Kenneth Lytts, thank you for your support, belief in me 
and sharing big moments with me during these years. We will rock together further!  
My colleagues at NKH now and in past, especially Ellen Holsvik Eckhoff, Stian 
Hammer, Sølvi Flaten, Solfrid Indrekvam, Heidi Markussen, Miriam Gjerdevik, 
Linda Tvedt, Sandra Rennedal, Haldis Mellingen, Astrid Smette, Nanette Mjellem, 
Sverre Lehmann and Bahareh Jouleh, for supporting me and for all the good times 
during office time and at conferences. Miriam, thank you for your fantastic friendship 
and especially for taking care of me during a difficult period of my life.  
Huge thanks to my parents Aino and Veikko, for raising me to be curios and for 
supporting me as I followed my own path. My lifelong friend Tarja, thank you for 
being on my side whatever happens. My gymnastics coach Heli, thank you for 
sharing your passion and teaching me the importance of hard work, already at a 
young age. My good friend Ina, thank you for inspiring me and being the most 
positive person I know. 
Finally, special warm thanks to my son Emil for being the light and joy in my life, 
and for making me smile every day. And last, but not least, I want to thank Roy 
Willy, my best friend and the love of my life, for being the most important part of my 
life and for shearing your life with me. Thank you for your endless support and belief 
in me, for always challenging me and for making me a better person. You two are the 
center of my universe, I love you!  
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1.3 Summary of thesis 
Background: Patients with amyotrophic lateral sclerosis (ALS) are treated with 
mechanical cough assist devices using the technique of mechanical insufflation-
exsufflation (MI-E) in order to improve cough and enhance clearance of airway 
secretions. The aim of treatment is to prevent lung infections and to provide a better 
quality of life. The technique often fails in ALS patients with bulbar involvement, 
allegedly due to upper airway malfunction. Laryngeal collapse during exsufflation 
has been proposed to explain the ineffectiveness of MI-E in bulbar ALS. However, 
there are a lack of studies utilizing comprehensive and verifiable methods to 
investigate the role played by the larynx of patients in whom MI-E appears to be non-
successful.   
Objectives: Study #I: To examine the feasibility of transnasal fiberoptic 
laryngoscopy (TFL) during ongoing MI-E in healthy volunteers, and to describe 
normal laryngeal response pattern(s) to MI-E. Study #II: To investigate laryngeal 
response patterns to MI-E in a cross-sectional study of ALS of different phenotypes. 
Study #III: To examine and describe changes in laryngeal response patterns to MI-E 
as ALS progresses, and to explore if treatment protocols can possibly be modified 
and improved in these patients. 
Design: Population-based, explorative, descriptive, observational studies, with cross-
sectional design in Study #I and #II, and prospective cohort design in the Study #III. 
Subjects: Study #I: Twenty healthy medical students. Study #II: Twenty patients with 
ALS together with 20 healthy volunteers, matched for age and gender. Study #III: 
Thirteen eligible patients with ALS, recruited from Study II, prospectively followed 
during disease progression for up to 5 years. 
Methods: ALS was phenotyped according to established international standards. 
Upper and lower motor neuron symptoms were characterized, and the respiratory 
function determined. Video recorded flexible TFL was applied during ongoing cough 
assisted by MI-E that was applied using various pressures according to a preset 




movements. The examinations were performed at outpatient visits that were 
scheduled at set time-intervals. 
Results: Study #I: The larynx could be studied with TFL during ongoing MI-E. The 
laryngeal responses to MI-E in healthy volunteers were compatible to that described 
in normal cough. Study #II: The laryngeal structures of patients with ALS and bulbar 
symptoms tended to adduct, especially during insufflation, which in some patients 
severely compromised the size of the laryngeal inlet, especially if high pressures were 
applied. Study #III: During ALS disease progression, the first signs of laryngeal 
adduction occurred with the highest insufflation pressures and prior to any clinically 
evident signs of bulbar involvement. Hypopharyngeal constriction during exsufflation 
was observed in all subjects regardless of bulbar symptoms, and later in the disease 
progression than the above described adverse events during insufflation. Cough 
gradually became less expulsive and also less synchronized at the laryngeal level. 
Triggering of swallowing reflexes by the positive air flow from the MI-E further 
complicated these matters. Attempts of careful individual tailoring of the MI-E 
therapy as the patients’ condition deteriorated seemed to prolong its successful use.  
Conclusions and interpretations: Laryngoscopy can safely be performed during 
ongoing MI-E, and appears a feasible tool to visualize the laryngeal responses to this 
therapy. In bulbar ALS, laryngeal structures are prone to adduct throughout the 
various pressure cycles of MI-E, especially if applying high insufflation pressures, 
thereby severely obstructing the airflow and thus hampering the effect of the 
treatment. Cough patterns alter as ALS progresses, and rapidly alternating MI-E 
pressure cycles may become challenging or even impossible to handle for patients. 
Individually tailored MI-E treatment can improve and may possible extend the use of 
non-invasive ventilatory support in ALS, and TFL can become a feasible and 
valuable tool in this respect.  
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AEF Aryepiglottic folds 
ALS Amyotrophic Lateral Sclerosis 
ALSFRS-r ALS Functional Rating Scale – revised 
BIS Bulbar impairment scale 
BS Bulbar score 
BMI Body Mass Index 
CI Confidence interval 
CLE Continuous laryngoscopy during exercise test  
CPAP Continuous Positive Airway Pressure  
CPF Cough Peak Flow 
CT  Computer Tomography 
EILO  Exercise induced laryngeal obstruction 
ENT Ear-Nose-Throat 
FEV1 Forced expiratory volume in the first second 
FVC Forced vital capacity 
EG Epiglottis 
MEP Maximal expiratory mouth pressure 
MI Mechanical insufflation 
MI-E Mechanical Insufflation-Exsufflation 
MIC Maximal insufflation capacity 
MIC>SCV Calculated difference between MIC and SVC  
MIP Maximal inspiratory mouth pressure 
MND  Motor neuron disease 
NKH Norwegian National Advisory Unit on Long-term Mechanical 
Ventilation 
NIV  Non-invasive ventilation 
PCA  Musculus cricoarytenoideus posterior 
PCF Peak cough flow 
PEF Peak expiratory flow 
PImax Maximal inspiratory mouth pressure  
PEmax Maximal expiratory mouth pressure  
RCT Randomised controlled trial 
RS Respiratory score 
SNIP Sniff nasal inspiratory pressure 
SVC Slow vital capacity 
TFL Transnasal fiberoptic laryngoscopy 
TVF True vocal folds 
USA  United States of America 
WST 100-ml water swallow test 
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2. Background 
2.1 Personal Introduction 
Respiratory management of people with neurological disorders has improved 
significantly during the two last decades. This positive development has occurred for 
a range of reasons, but has primarily been due to an increased interest and volume of 
knowledge within the medical community, accompanied by technological advances. 
A better understanding of the pathogenesis of chronic respiratory failure, and the role 
played by weak cough have been important. In Norway, the Norwegian National 
Advisory Unit on Long-term Mechanical Ventilation (previously labeled The 
Norwegian Centre of Excellence for Home Mechanical Ventilation) was established 
in Bergen in 2002, with the aim to increase the quality of life of persons on long-term 
mechanical ventilation, and to facilitate equal access to evidence based treatment 
across Norway for patients with chronic hypoventilation. I have been employed by 
this institution as a respiratory physiotherapist with responsibility for airway secretion 
management since it was established.  
The prevailing clinical impression is that MI-E in most neuromuscular patients 
contributes to more efficient clearance of airway secretions, improved management 
of chest colds and prevention of severe chest infections, and that requirement for 
hospitalizations and even tracheostomy can be reduced. However, patients with ALS 
and bulbar dysfunction have been particularly challenging to treat successfully with 
MI-E, allegedly due to disturbed laryngeal responses. This clinical observation is 
poorly understood, and has not been thoroughly investigated using comprehensive 
and verifiable methods. (Literature search has been done regularly since October 
2010 and for the last time on 5th December 2017). 
In our hospital (Haukeland University Hospital, Bergen, Norway), transnasal 
laryngoscopy is being extensively used as a diagnostic tool in a variety of functional 




laryngeal obstruction (EILO). Inspired by these examinations, I decided to use 
laryngoscopy during ongoing mechanically assisted cough in patients with ALS in 
order to increase our understanding of why MI-E fails to help some of these patients, 
and - hopefully - to contribute to improving their airway clearance therapy. This idea 
constitutes the basis for my PhD thesis. 
2.2 Amyotrophic Lateral Sclerosis 
2.2.1 Definition 
Amyotrophic Lateral Sclerosis (ALS) is a fatal, highly disabling and incurable 
neurodegenerative disease of upper and lower motor neurons.1-3  
Charles Bell, a British anatomist and surgeon, reported the first ALS case in 1830, 
describing a condition that caused progressive paralysis of the limbs and tongue. The 
first to describe ALS as an entity was the French neurologist Jean-Martin Charcot; 
hence ALS is also known as Charcot disease. The condition gained more widespread 
attention after the very popular American baseball player Lou Gehrig was diagnosed 
with ALS in 1939.4 In Europe and in USA the term Amyotrophic Lateral Sclerosis 
(ALS) is used, while in Australia and United Kingdom the term Motor Neuron 
Disease (MND) is preferred.5 
The pathogenesis of ALS is poorly understood.6 The disease is heterogeneous in its 
presentation and progression; e.g., with variabilities as regard the presence and the 
timing of onset of upper and lower motor neuron signs. Upper motor neurons have 
their origin in the motor cortex. Their axons travel through the great corticofugal 
tracts to the brain stem (corticobulbar neurons) and to the spinal cord (corticospinal 
neurons) to influence the patterned activity of the lower motor neurons.7 Upper motor 
neuron abnormalities lead to spasticity and hyperreflexia, while abnormalities of 
lower motor neuron entail flaccidity and hyporeflexia in addition to muscle atrophy 
and fasciculation.8,9 The motor deficits in ALS are often mixed and encompass both 
flaccid and spastic weakness.8-11  
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The initial clinical findings and symptoms in ALS are characterized either as spinal 
onset with clinical symptoms from the arms and/or legs, or as bulbar onset, with 
clinical symptoms primarily being difficulties with speech, swallowing and coughing. 
Regardless of the type of onset, muscle weakness and atrophy will, as the disease 
progresses, eventually involve all skeletal muscles.3,12 Spinal onset ALS with 
gradually progressive weakness of arms or legs is the most common initial clinical 
presentation, occurring in about 70% of cases. About 25-30% of ALS patients have a 
bulbar onset disease, however, this is less common in younger patients and more 
common in older patients; i.e. occurring in 43% of those over 70 years.13 The 
patients’ history together with the clinical neurological examination commonly 
establishes the diagnosis and the subtype of ALS, in accordance with the El Escorial 
World Federation of Neurology revised criteria.14,15 Some few ALS patients have 
documented signs of frontotemporal dementia, characterized by cognitive and 
behavioral dysfunction associated with changes in personal and social conduct.4   
The causal factors leading to ALS are still unknown, and both environmental and 
genetic factors are assumed to be involved.16,17 Authors have suggested that a high 
level of physical activity might modulate the risks of ALS, with increased risk among 
e.g. professional football players and in subjects with a body mass index (BMI) 
below average.18,19 About 10% of ALS cases have a family history of the disease, and 
over 20 genes linked with familial ALS have been identified. Almost all familial 
cases have an autosomal dominant inheritance.16  
2.2.2 Epidemiology  
ALS is a rare disease; however, it is considered frequent among rare diseases.16 A 
wide range of ALS incidence and prevalence rates have been reported in various 
populations.17,20 In Europe, the reported annual incidence varies from 0.5/100 000 in 
Belgrade21 to 3.6/100 000 in the Faroe Island,22 and the prevalence varies from 
1.1/100 000 (95% CI, 0.71–1.71) in “old” Yugoslavia21 to 8.2/100 000 (95% CI 2.1–
20) in the Faroe Islands.22 The prevalence in Hordaland county in Norway, where our 




ALS onset is typically around 60 years of age.2 The incidence is highest in people 
aged 55–79 years, and onset below the age of 40 years is uncommon.24 There is a 
modest male predominance. While bulbar onset has no gender prediction, the spinal 
onset is more common in males.25 People older than 80 years have a standardized 
incidence of 10.2/100 000 in men and 6.1/100 000 in women.26 
2.2.3 Prognosis  
Involvement of respiratory muscles limits respiratory function and cough which leads 
to accumulation of secretions, increased risk of lung infections and eventually 
respiratory failure. In the end-stage of the disease, this strongly impacts quality of life 
and survival. Signs and symptoms of the disease increase as the disease progresses. 
Since there is no cure for ALS, the treatment is largely symptomatic and 
palliative.1,12,13,27,28 
Most patients with ALS die within 2–3 years of developing the first symptoms, but 
20% of patients survive for 5 to 10 years.29 The median post-diagnosis survival time 
has increased over the last decade; 29 months for patients diagnosed before the year 
2000 vs. 36 months for those diagnosed during 2000–2009.30 This is most likely due 
to better access to multidisciplinary clinics and better treatment. A poor prognosis is 
associated with older age at disease onset, quick development of respiratory muscle 
weakness and bulbar onset.5 Also rapid progression of bulbar or respiratory 
symptoms negatively influences outcome.20 Contrary, limb onset, younger age at 
disease onset and longer diagnostic delay are independent predictors of prolonged 
survival.29,31,32 
Care of the ALS patient focuses on maintaining function and quality of life.24 
Respiratory complications are life threating in ALS and a proactive preventive 
approach is a key element in disease management. Non-invasive ventilatory support 
and mechanically assisted cough are mainstay therapeutic techniques;33,34 however, 
non-invasive methods are challenging to use and tend to fail in ALS when bulbar 
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dysfunction is present.33,35-37 This is an unfortunate situation that hampers treatment 
success, particularly as the disease progresses.  
2.2.4 Bulbar innervated muscel weakness 
Muscles of the jaw, face, soft palate, pharynx, larynx and the tongue are innervated 
by neurons located in the so-called bulbar region of the brain stem.11 The bulbar 
region of the brain encompasses the lower brainstem, pons and medulla.38 Bulbar 
innervated muscle dysfunction leads to so-called bulbar symptoms, such as weakness 
of pharyngeal muscles, spasticity or lack of coordination of laryngeal or lingual 
muscles.39,40 
Clinically, bulbar involvement in ALS can primarily be characterized by either 
spasticity or flaccid paresis and atrophy, depending on the extent of upper versus 
lower motor neuron involvement, the former usually labeled pseudobulbar palsy and 
the latter progressive bulbar palsy, or a combination. ALS mainly involving the 
upper motor neurons leads to pseudobulbar palsy which is clinically characterized by 
spasticity of the bulbar innervated muscles, emotional lability (e.g. pathological 
laughing and crying) and an enhanced masseter reflex (jaw jerk reflex). ALS mainly 
involving the lower motor neurons leads to progressive bulbar palsy which is 
clinically characterized by flaccid paresis and muscular atrophy, and fasciculation of 
the tongue (i.e. small, local, involuntary muscle contraction and relaxation) and/or 
tongue fibrillations (rapid, irregular, and unsynchronized contraction of muscle 
fibers).11 
Dysarthria (difficulties to articulate and pronounce) and dysphagia (difficulties to 
swallow) are frequent features of bulbar symptoms in ALS, and can reduce quality of 
life and life expectancy. Dysarthria results from flaccid or spastic paresis of the 
bulbar innervated musculature. Dysphagia can result from weakness or spasticity of 
the muscles innervated by trigeminal, facial, hypoglossal, glossopharyngeal or vagal 
nerves.11 Laryngospasm (uncontrollable muscular contraction of the vocal folds) is 




Bulbar innervated muscle dysfunction is a huge challenge in the respiratory treatment 
of ALS, since upper airway stability is fundamental to the delivery of non-invasive 
respiratory aids to the lungs. Thus, bulbar muscle dysfunction is often associated with 
ineffective non-invasive respiratory management.33,36,37,42 Bulbar insufficiency also 
corrupts effective cough, and thereby prevents removal of airway secretions.35 ALS 
patients commonly report episodes of ineffective cough and episodes of choking 
when bulbar function deteriorates beyond a critical level.43 
2.3 Larynx 
The larynx functions as a valve to the airways with three major functions:  
1) To control airflow during respiration.  
2) To protect the lungs from aspiration. 
3) To play a key role in phonation.44-47 
2.3.1 Anatomy 
The larynx is located in the throat. The laryngeal inlet is situated at the inferior part of 
the pharynx (hypopharynx), and the larynx extends from the tip of the epiglottis, 
through the true vocal folds to beneath the border of the cricoid cartilage. See Figure 
1 for illustration.The larynx consists of rigid cartilage skeletons, ligaments and 
muscles for adduction and abduction.44  
 
Figure 1. Side view of the larynx. 
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The intricate skeleton of hyaline and nine elastic cartilages are connected to each 
other by joints and elastic ligaments.48,49 The aryepiglottic folds connect the epiglottis 
and arytenoid cartilage on either side of the midline.50 Within the mucous membrane, 
there are two tubercles (corniculate tubercle and cuneiforme tubercle) formed by the 
two cartilages of the corresponding name. The laryngeal muscles can be described as 
either intrinsic or extrinsic, and they are under voluntary as well as involuntary 
(reflex) control. The larynx is innervated by the internal branch of the superior 
laryngeal nerve and the recurrent laryngeal nerves; both branches of the vagus 
nerve.51  
2.3.2 Extrinsic and intrinsic muscles 
The laryngeal extrinsic muscles can be referred to as strap muscles. They control the 
position of the larynx in the neck and are particularly important in swallowing, which 
involves elevating and depressing the larynx in the longitudinal axis.52 Musculus 
cricothyroideus is the only extrinsic muscle that tightens and lengthens the true vocal 
folds. 
The small intrinsic laryngeal muscles move the laryngeal structures in relation to 
each other. They are essential in breathing, speech, cough and swallowing where they 
interact in complex manners, but always act in concert.48,49,53 The larynx has several 
small intrinsic adductor muscles, but only one abductor muscle; musculus 
cricoarytenoideus posterior (the PCA muscle). It operates in a coordinated and phasic 
relationship with the diaphragm, meaning that diaphragmatic vagal stimulation is 
coupled with increased activity of the PCA muscle, leading to laryngeal abduction 
and thereby opening of the laryngeal inlet immediately before diaphragmatic 
contraction.54 
Abduction and adduction 
Abduction of the glottis is fundamental for free airflow in and out of the lungs during 
respiration with the least possible resistance. During normal quiet breathing, the 
glottis widens during inspiration and narrows during expiration. This widening occurs 




expiration.55,56 Both forced inspiration and expiration are associated with increased 
activation of the intrinsic laryngeal muscles.57 Figure 2 demonstrates an open and 
closed glottis as viewed laryngoscopically. 
 
 
                              OPEN (DEEP INSPIRATION)                  CLOSED (GLOTTIC CLOSURE) 
Figure 2. Top view of the larynx; open and closed glottis. 
Tight adduction of the true vocal folds, together with the activity of the aryepiglottic 
muscles lead to closure of the inlet of larynx by bringing the aryepiglottic folds tight 
together. This enables the larynx to withstand the high pressures that can be generated 
in the thorax, e.g. during cough.58 Varying degrees of laryngeal occlusion are also 
involved in speech.52 During swallowing laryngeal occlusion is combined with a 
lifting of the larynx and elevating of the epiglottis in order to prevent the food bolus 
(i.e. the mass of food formed in the mouth, mixed with saliva) from entering the 
airways.58,59   
Opening and closure of the glottis require complex and concerted intrinsic laryngeal 
muscle contractions involving similarly complex neural interactions that are only 
partially understood.60,61 Stimulation of extremely sensitive receptors in the 
supraglottic larynx induce complex adductor reflexes that, for example, prevent 
foreign bodies from entering the airways.54  
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The larynx is considered to mature throughout puberty and little is known regarding 
inter-individual variability throughout adult life in healthy individuals. A gradual 
development of laryngeal structure and function from infancy to adulthood has been 
described, characterized by maturation of the cough reflexes and improved 
coordination and strength of the muscles that are involved in cough.62-64  
Cough at the laryngeal level 
At the laryngeal level, a normal cough requires intrinsic laryngeal muscle 
contractions60,61 and consists of three distinct phases:  
1) An initial abduction to allow airflow into the lungs.  
2) A closing phase (0.2 seconds) to allow build up of intrathoracic pressure.   
3) A secondary abduction of the true vocal folds to allow high expiratory 
airflow. The expiratory phase of cough can also present with a varying number 
of sequential glottic closures and openings.65-67 
During the closing phase, closure of the true vocal folds is followed by closure of the 
supraglottic structures. These movements are further aided by squeezing of the 
pharyngeal walls, collectively creating a supraglottic sphincter.66 A reflex cough is 
mediated (afferent) through the vagal nerve, while volitional cough is mediated 
through corticobulbar pathways.43 
2.3.3 Aerodynamics 
The larynx can be described as the bottleneck of the airways68 accounting for a 
significant fraction of total airway resistance. The type of the airflow, either laminar 
or turbulent, contributes to airflow resistance of the airways; turbulent airflow 
generating more resistance than laminar airflow. Most of the turbulent airflow is 
shown to be located in upper airways; i.e. in the nose during nasal breathing and in 
the mouth, pharynx, glottis, larynx and upper trachea during mouth breathing. 
Especially at higher airflow rates, the resistance in the larynx becomes proportionally 




Increased airflow through the larynx may result in an aerodynamically induced 
laryngeal narrowing, or even a collapse of laryngeal structures. This is explained by 
the Bernoulli principle witch states that as the velocity of gas increases, the pressure 
exerted by the gas decreases. Translated into the laryngeal environment, this means 
that increasing airflow velocity leads to an increasing negative pressure inside the 
laryngeal lumen and then to an increasing inward pressure on the laryngeal 
architecture. The consequence of this is that the high airflows through the larynx may 
lead to negative pressures that may overcome the stability of the organ and thus lead 
to the structures being sucked inwards.70 To prevent this happening, the forces of 
muscular contraction and tissue elasticity/rigidity together try to keep the larynx 
open, allowing a passage for air in and out of the lungs.44 
2.3.4 Laryngeal effects of mechanically applied pressures 
In healthy awake subjects, passive progressive positive pressure ventilation results in 
progressive glottic narrowing, occurring especially in the absence of diaphragmatic 
activity. The glottic narrowing during positive pressure ventilation increases the 
inspiratory resistance and reduces progressively the fraction of delivered minute 
ventilation reaching the lungs.71 
The Bernoulli principle at the laryngeal inlet have been suggested to be causally 
involved in the condition known as floppy epiglottis during Continuous Positive 
Airway Pressure (CPAP) therapy. In this condition, the epiglottis is sucked into the 
laryngeal inlet during inspiration assisted by an externally applied positive pressure.72 
Negative pressures applied in the expiratory phase of the respiratory cycle in healthy 
subjects have been described to provoke partial or total narrowing of the upper 
airway at the pharyngeal and the oropharyngeal level, and thus decrease expiratory 
flow rates.73-75  
2.3.5 Laryngeal evolvement in ALS 
Several neurological conditions with impairment of sensory afferents, abnormal 
reflexes, poor coordination or motor weakness can severely disrupt laryngeal 
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function.76 Thus,  problems of upper airway function are frequently encountered in 
ALS39,77 and laryngological presentations of ALS are described in the literature,39,78-82 
particularly in relation to distinguishing between bulbar versus spinal onset 
ALS.39,78,83  
Bulbar innervated involvement in ALS leads to abnormalities of the control and 
strength of the laryngeal and pharyngeal muscles.39,40 Hillel and Miller described the 
typical progressive pattern of bulbar ALS, affecting firstly tongue and lips, secondly 
the palatal-, jaw- and pharyngeal muscles, thirdly facial-, upper trunk-, and laryngeal 
muscles, and finally the extra-ocular muscles. As a result of the order in which the 
muscles are being affected, swallowing difficulties are one of the earliest complaints 
reported by patients with bulbar ALS.84 The tongue muscle deficit has been suggested 
to be the major factor causing swallowing difficulties in ALS.85 Signs of laryngeal 
involvement can also include failure of the larynx to move superiorly and anteriorly 
during the swallowing, leading to incomplete closure of the larynx and thus a risk of 
aspiration.84 Additionally to the reduced muscle strength and control, abnormal 
sensory function at the laryngeal level has been described in ALS,86,87 and sensory 
deficits are more frequent in bulbar than in spinal onset ALS.87 Also an impaired 
laryngeal adduction reflex43 (the sensorimotor response that protects the airways from 
aspiration during and after swallowing) has been demonstrated in ALS.85 
Pharyngeal and laryngeal complications lead to increased risk of aspiration, and 
eventually a need for the patient being fed via a percutaneous endoscopic gastrostomy 
tube.80 Inability to coordinate the true vocal folds as well as weak expiratory muscle 
strength, impairs the compressive and expulsive characteristic of the cough,88 
challenging non-invasive management of airway secretions.33,36,37,42  
2.4 Respiratory management in ALS 
Respiratory insufficiency and pneumonia are the primary causes of comorbidity and 




techniques are critical components of respiratory management in ALS, and are often 
used in conjunction.33  
2.4.1 Respiratory muscle weakness  
In patients with ALS, respiratory muscle function is a strong predictor of quality of 
life28 and survival.89 The respiratory muscle weakness is a major clinical feature of 
ALS24,90 and may affect all the respiratory muscles; both inspiratory- and expiratory, 
and the muscles controlling the upper airways.91 It decreases both voluntary and 
reflex coughing, and eventually leads to respiratory failure.11  
The progressive picture of respiratory muscular weakness in ALS contributes to 
lower functional lung volumes, decreased gas exchange and alveolar ventilation. 
Respiratory muscle weakness leads to ineffective cough, leading to further 
accumulation of airway secretion, pulmonary infections, atelectases, pneumonias and 
disturbed gas exchange.92  
Upper airway muscle weakness often leads to accumulation (pooling) of saliva or 
secretions in larynx, drooling (unintentional loss of saliva from the mouth) and 
aspiration (passage of material into the level of the vocal cords). Drooling is often 
regarded socially unpleasant, and may represent an additional burden to the more 
serious medical problems of aspiration. Aspiration of food, liquids or nasopharyngeal 
or oral secretions can lead to aspiration pneumonia.10,92  
Figure 3 illustrates pathological consequences and interactions from respiratory 
muscle weakness observed in people with neuromuscular disorders. Since ALS is a 
very rapidly progressing disease, the lung function deteriorates similarly rapidly. In 
fact, the pathological processes may evolve so quickly that the respiratory 





































Figure 3. Pathologic consequences and interactions from respiratory 
muscle weakness in neuromuscular diseases. 
2.4.2 Home mechanical ventilation 
Mechanical ventilation is provided by positive pressure devices in the presence of 
daytime hypercapnia, symptomatic sleep-disordered breathing, and deteriorating 
pulmonary function. Technical development during last 100 years has provided 
ventilatory support that can be applied at home by means of small portable devices 
via a non-invasive interface, i.e. a nasal-mask, a face-mask or a mouthpiece.36 Home 
mechanical ventilation is widely provided in neuromuscular disorders and 
predominantly delivered by non-invasive mechanical ventilation (NIV) without need 
for tracheostomy.93 In contrast to other neuromuscular conditions, the use of 
ventilatory support in ALS has been evaluated using a randomized controlled study 
design.94,95 NIV increases the average survival especially in patients with mild to 




bulbar impairment NIV had benefit in quality of life, but not in survival.94 NIV may 
be most beneficial for quality of life when it is started before patients becomes 
symptomatic for hypoventilation.95 Successful application of NIV requires adequate 
bulbar function to allow for sufficient airflow to the lungs,42,96,97 and a preserved 
ability to cough and to remove airway secretions.33,45,98  
Invasive mechanical ventilation and airway clearance via a tracheostoma cannula can 
compensate for these issues; however, it is less widely chosen in ALS since 
tracheostomy involves complex ethical issues and can have adverse effects on quality 
of life,42 and also involves a greater burden of caregiving and financial costs.33,99-104 
Thus, to choose tracheostomy in ALS requires careful consideration in each 
individual patient.105 There are no clinical guidelines that advice on the optimal 
timing to perform a tracheostomy in relation to increasing bulbar dysfunction and 
patients’ deterioration.106 
In summary, mechanical ventilation, both non-invasive and invasive, can extend life 
and improve respiratory symptoms in ALS.37,91,94,107-111 However, non-invasive 
methods are often challenging in bulbar ALS patients.37,94,107  
2.5 Airway secretions 
2.5.1 Defense mechanism of the lungs  
The respiratory tract from the nasal cavity to the bronchioles is covered by ciliated 
epithelium that contains mucus-secreting cells (goblet cells). Goblet cells together 
with submucosal secretory cells, produce a thick layer of mucus that lines all but the 
smallest conducting airways.59 The airway mucus catches foreign particles, such as 
dust and micro-organisms that are inhaled into the lungs with the air during breathing. 
This mechanism prevents foreign particles from reaching the alveoli, where gas 
exchange takes place. Mucus is normally transported to the oropharynx by the airway 
clearance mechanism.112-114 The airway secretions have an important role in the 
defense mechanisms of the lungs, and defective airway clearance can have serious 
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consequences as accumulation of airway secretions will lead to infections, atelectasis, 
increased airway resistance, increased work of breathing, hypoxemia, and eventually 
contribute to increased mortality.88  
2.5.2 Normal airway clearance  
Pheripheric airways 
Airflow bias is the label used to describe an important phenomenon that occurs 
naturally in the airways during normal breathing. The mechanism implies that the 
diameter of the airways widens on inspiration and narrows on expiration, with 
unchanged inspiratory and expiratory volumes and times. Narrowing of the airways 
during exhalation will increase linear velocity and thus enhance the shearing forces in 
the airways during normal tidal breathing, as well as in deeper voluntary breaths and 
during sighs, thereby contributing to clearance of airway secretions. Airflow bias is 
also a contributing factor to the clearance of secretions from the larger airways, and it 
may be amplified during a cough.114 
The ciliated epithelial cells contribute to moving the mucus layer towards the upper 
airways at the rate of 4 mm/min,59 until the so-called isothermic saturation boundary 
is reached. This is the level of the airways where inspired gas is humidified to 100 % 
and heated to body temperature (37°), and is usually located at the 3rd to 5th 
generation of the bronchial tree during quit breathing.115,116  
Typically, people with neuromuscular disorders have no abnormalities of these so-
called mucociliary escalator mechanisms, unless a chronic aspiration scenario has 
been established or a chronic lung disease has evolved. 
Proximal airways 
Cough is a crucial element among the defense mechanisms of the airways,117,118 
particularly as regards removing airway secretions from the central airways.119,120 The 
central airways contain irritant sensors that may become reflex triggered by mucus 
surplus or other physical or chemical irritants, subsequently inciting reflex cough.43,67 
An effective cough depends on coordinated and forceful movements from several 




- Inspiratory muscles to increase the lung volume up to 85 – 90 % of the total 
lung capacity. 
- Expiratory muscles to increase the thoraco-abdominal pressure to as high as 
400 cmH2O during glottic closure. Upon glottic opening, this enables 
extremely vigorous expiratory efforts and high expiratory flow rates, with peak 
cough flow in the range of 360–1200 liters/min. 
- Laryngeal intrinsic muscles to facilitate finely tuned coordinated glottic 
openings and closures.67,121,122 
During the expulsive phase of cough, the releasing pressures and the high expiratory 
flow rates shear the secretions from the airway walls and move the secretions 
upwards. This phase can be interrupted by short sequences of glottic closures and 
openings, each with compressive and expulsive phases, which can be seen as a series 
of airflow spikes on a maximal expiratory flow volume curve.123 For details, please 
see Figure 4.  
Peak cough flow is the highest measured airflow spike during cough, usually 
appearing immediately after the glottic opening phase of the cough cycle. When 
measuring peak cough flow, the person is simply encouraged to inhale deeply and 
then actively cough via a mask or a mouth piece into to a peak flow meter.124 Peak 
cough flow is a measure of the person’s ability and (indirectly) strength to cough, 
normal values in adults exceed 360 liters/min.125  
Effectiveness of airway clearance in neuromuscular diseases has been shown to be 
related to peak cough flow.120,126-128 Thus, techniques to augment coughing and to 
increase peak cough flow are recommended to prevent chest infections in 
neuromuscular disorders,129-131 with peak cough flow of 160 liters/min considered a 
minimum for effective airway clearance.120,126,132,133 Persons with neuromuscular 
disorders can be further weakened by acute episodes of viral illnesses. This has been 
linked to decreased inspiratory and expiratory muscle strength induced by the viral 
illness, leading to lower vital capacity and thus less effective cough.134  
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Figure 4. Airflow spikes with the peak cough flow (PCF) during the 
expiratory phase of cough illustrated by the flow volume curve measured 
during a cough maneuver.  
2.5.3 Airway clearance in respiratory physiotherapy 
Respiratory physiotherapy is a multifaceted discipline and consists of examination, 
assessment and evaluation of function, interventions, exercise and therapy to facilitate 
breathing, respiratory care and airway clearance, and - not least - education and 
advice on self-management.130,135 
Airway clearance, also referred to as mucus clearance or secretion clearance, is one of 
the main elements in respiratory physiotherapy and a critical aspect of respiratory 
care.88 Therapeutic airway clearance regimens should be effective, efficient, easy to 
use and teach, possible to carry out independently or with an assistant, and should 
improve lung function without being perceived as uncomfortable or causing 
hypoxemia. It should be flexible and adaptable to the changing needs of the 
individual patient.136 
Physiotherapy techniques to clear airway secretions should support mucociliary 
clearing (peripheral techniques) and augment cough (proximal 
techniques).104,124,136,137 The choice of technique depends on the patients’ 
physiological and functional deficiencies rather than the medical diagnosis.129 In 
primary pulmonary diseases, such as cystic fibrosis, primary ciliary dyskinesia, 




clearance is related to impaired mucociliary escalator mechanisms, and the 
physiotherapy techniques should therefore support peripheral airway clearance.88 In 
neuromuscular disorders such as ALS, the impaired airway clearance is related to 
impaired cough due to respiratory muscle weakness, and the physiotherapy 
techniques should therefore focus on augmenting the cough. Some circumstances in 
neuromuscular disorders, for example during acute pulmonary infections, increased 
production of airway mucus and obstructions in the airways, the need for the 
institution of additional peripheral airway clearance techniques may be 
warranted.124,137  
The aim of respiratory physiotherapy and airway clearance techniques applied to 
persons with neuromuscular disorders is to increase inspiratory volumes and 
expiratory flow.129,130 Cough augmentation should target both of these aspects.88,124,138 
The techniques physiotherapists use to assist cough often combine assisted 
insufflation of the lungs with expiratory support. Insufflation can be delivered by the 
technique of air stacking (repeated inspirations without breathing out) with manual 
resuscitator, mechanical device delivering positive pressure, or with glossopharyngeal 
breathing (self-air-stacking by using the mouth, tongue, pharynx and larynx to 
compensate for the weakness of the inspiratory muscles). Expiratory support can be 
provided either manually by thoraco-abdominal thrust or mechanically by 
exsufflation. Mechanical insufflation-exsufflation (MI-E) is a mechanical technique 
to assist cough combining both inspiratory and expiratory support.88,124,139  
2.5.4  Airway clearance therapy in ALS 
The aims of airway secretion therapy in ALS are to relieve the symptoms and the 
discomfort related to the accumulation of secretions, and to prevent and treat 
pneumonias. The need for assisted airway clearance techniques increases when the 
respiratory muscles become progressively weaker.33,34  
In patients with ALS, peak cough flow below 270 liters/min during acute episodes 
suggests an ineffective cough, and therefore it is recommended that these patients 
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start using assisted cough techniques on a daily basis to prevent chest infections.140 
MI-E is regularly used in ALS.132,141-145 Additional techniques that have been 
described are manually assisted cough, air stacking techniques, lung volume 
recruitment techniques, postural drainage and manual techniques (shaking, percussion 
and vibrations), active cycle of breathing technique, intrapulmonary percussive 
ventilation, humidification and mouth- and airway suction.24,104,137,139,146-152  
2.6 Mechanical Insufflation-Exsufflation 
MI-E is widely used in patients with neuromuscular disorders to assist and augment 
cough by applying positive and negative pressure changes to the airways, either non-
invasively via a mask or invasively via a tracheostomy.117,119,128,131,141,143-145,153-158  
When the patient inhales, the MI-E supports the inspiratory movement by delivering 
a positive pressure (insufflation), contributing to a better expansion of the lungs. This 
is followed by a rapid switch (10 milliseconds) to a negative pressure, supporting the 
expiration (exsufflation) of the patient’s lungs. These positive and negative pressure 
swings are applied sequentially. The rapid switch from positive to negative pressure 
aims to simulate the airflow changes that occur during normal cough, potentially 
facilitating secretion clearance.153 A voluntary cough maneuver is desired when using 
MI-E, and patients must learn to co-ordinate their own cough movements (i.e. glottic 
openings and closures) when the device switches from insufflation to exsufflation.159 
The treatment is tolerated by most patients with neuromuscular disorders, and it is 
considered a safe method for cough clearance.119,155-157,160-162 
2.6.1 Clinical use 
In Norway, MI-E devices became available in 2001, and currently the Norwegian 
public health care system provides MI-E for eligible patients in home setting.163 The 
most commonly used MI-E device in Norway is Cough Assist® (Respironics, 





MI-E devices can in principle be operated in two modes: manual or automatic. In 
both modes settings entail pre adjustment of the positive and negative pressures 
(cmH2O) and the inspiratory flow rate (liters/min). The automatic mode setting 
entails pre adjustment of the duration (timing) of the insufflation, exsufflation and the 
interval between the exsufflation and next insufflation (pause), when in manual mode 
this is operated during the therapy by the therapist. A new device from 2013 (Cough 
Assist E70®) also allows for patient triggered insufflation, as well as oscillations with 
interruptions of the insufflation and/or exsufflation pressures and flows. 
Physiotherapists use MI-E to increase chest expansion (lung recruitment) during 
inspiration and to assist the expiratory cough movements as a part of the total 
respiratory physiotherapy treatment. The clinical use of MI-E is a dynamic process, 
involving to a large extent patient interactions. It is important to build up a good chest 
expansion by utilizing the assistance provided by the applied positive pressure during 
inspiration, and subsequently to adjust the negative pressure during exsufflation so 
that the audible quality of the cough reaches the desired and adequate levels. MI-E is 
often combined with manually assisted cough; i.e. the therapist manually providing 
abdominal thrusts coordinated with the patients cough movements during the 
exhalation phase.159 The daily respiratory treatment of ALS patients usually takes 
place at the patients’ home, and is usually performed by personal caregivers 
according to individually tailored procedures that are planned for home use. One 
treatment session with MI-E usually consists of several phases of coughing and rest, 
involving repeated cycles of insufflations and exsufflations, followed by 
approximately 30 seconds of rest. An additional thoraco-abdominal thrust applied by 
the therapist or by an assistant can be provided during exsufflation. These cycling 
periods are repeated several times or until secretions are substantially expelled.153  
2.6.2 Settings 
When using MI-E for individual patient treatment, the settings of positive and 
negative pressures, flow rates and time intervals should be adjusted to ensure 
reasonable patient comfort, and facilitate a deep inspiration that provides as good 
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chest expansion as possible, subsequently followed by timing and pressure settings 
during expiration that allow for optimal cough movements, capable of mobilizing 
secretions.159  
Pressure 
The literature varies regarding suggestions of what are optimal inspiratory and 
expiratory pressure settings, ranging from 20 to 60 cmH2O in positive and negative 
pressures.124,153 High pressures of ±60 cmH2O have been described and used by Bach 
and co-workers.128,133,157,164-167 However, lower pressures have been reported by other 
researches; ±30 cmH2O156 and +20 cmH2O to -30 cmH2O.119,168 Pressure settings of 
±40 cmH2O appear to be a good compromise between efficacy and 
comfort.117,151,153,169 Higher pressures have been proposed to be necessary when lung 
mechanics change during progression of the illness,170 in scoliosis117 or if used via a 
tracheostomy cannula.171  
Insufflation flow 
The insufflation flow rate used with the Cough Assist® device can be adjusted to 
either high flow (10 liters/min) or low flow (3 liters/min).159 The optimal inspiratory 
flow settings when MI-E is applied in various disease conditions, have not been 
investigated in properly designed studies.  
Oscillation 
During the cycles of insufflation, exsufflation, or both, the Cough Assist E70 device 
can apply high-frequency oscillatory vibrations, generated by air pulses. Settings 
entail pre adjustment of the oscillation frequency within the range of 1-20 Hz, and the 
amplitude of oscillations within the range of 1-10 cmH2O. Theoretically, these high 
frequency oscillations may facilitate the loosening of thick secretions, enabling them 
to be cleared.172 This assumption is based on studies showing that the application of 
high frequency oscillations of airflow in the airway to change the viscoelastic 
properties of the secretions, making them more mobile.173,174 Recently, a study by 
Sancho et al. demonstrated that addition of oscillations to MI-E does not have effect 





The time settings applied with the various MI-E phases is mainly based on 
experience, and has not been investigated in properly designed studies. A study by 
Gomez-Merino et al. demonstrated that increasing the insufflation time is more 
important for optimal peak cough flow than increasing the exsufflation time.175  
2.6.3 Effect 
The effect of MI-E in neuromuscular disorders is mainly linked to its ability to 
increase peak cough flow to the level required to eliminate airway secretions, and 
thereby augment airway clearance.117,119,128,131,141,143-145,153-158 A review from 2005131 
concluded that the use of MI-E is the most effective physiotherapeutic approach to 
increase peak cough flow and to maintain vital capacity in patients with 
neuromuscular disorder.119,132,133,143,157 
A Cochrane systematic review of randomized controlled trials (RCT) using MI-E in 
neuromuscular disorders, failed to demonstrate any conclusive benefits as regards 
mortality, morbidity, or quality of life for patients or any serious adverse events from 
the treatment.176 A recent review that also incorporated case series, cohorts and other 
pre-post trial designs other than RCTs, concluded that improvements of peak cough 
flow was consistently reported by all 12 studies; however, none of them reported 
survival advantages. Two of the studies (n=21 patients) found no change in hospital 
length of stay; however, two studies found a decrease in respiratory exacerbation 
rates, and improvements in quality of life were observed across a number of studies 
(n > 100 patients). None of the studies objectively measured sputum quantity. 
Further, the heterogeneity of the applied outcome measures complicated the summary 
statistics.177  
Despite these limitations, most relevant international guidelines recommend the use 
of MI-E, supporting the view that “absence of evidence of effect is not evidence of 
absence of effect”.137 
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2.6.4 MI-E in ALS 
Most literature suggests that MI-E is most efficient in ALS patients without bulbar 
dysfunction.132,141-145 Particularly, in patients with bulbar involvement MI-E is less 
effective at increasing peak cough flow to the levels considered necessary for 
effective removal of airway secretions.141,143 To increase understanding of this 
observation, Sancho et al. examined three patients with ALS at baseline conditions 
and during application of mechanical exsufflation with a computer tomography (CT) 
scanning of their upper airways (pharynx and oropharynx). They found that failure to 
increase peak cough flow to an adequate level was associated with a dynamic 
collapse of the upper airway during exsufflation. Although they did not examine 
directly the laryngeal level of the upper airways, they used their findings to suggest 
that coordinated movements of the glottis and intact bulbar function are necessary 
elements for effective use of non-invasive MI-E.141  
It is a well-established clinical experience that the response to MI-E in patients with 
ALS is variable, but it is difficult to predict beforehand in whom the method will 
succeed and in whom it will not. Non-responders tend to express a sense of being 
“unable to breath in or out” with the device. In practice, a therapeutic trial is 
conducted in most neuromuscular patients with a manifested cough problem. 
The knowledge obtained from the study of Sancho et al141, and the assumptions made 
by other authors fit my own clinical experience as a respiratory physiotherapist, and it 
supports the hypothesis that preserved laryngeal function is crucial to the 
effectiveness of MI-E.  
Nevertheless and surprisingly, laryngeal movements and patency during ongoing MI-
E cycles applied in patients with neuromuscular disorders has yet to be studied. 
2.7 Transnasal fiberoptic laryngoscopy 
Transnasal fiberoptic laryngoscopy (TLF) was first performed in the late 1960s, and 
has since proved to be a well-tolerated examination that provides a direct view of the 




and interpret outside the immediate examination context. This is particularly 
important in a study context, as the findings thereby can be made available for 
multiple assessors and also verifiable by others. TFL can relatively easily be 
performed by otolaryngologists or other trained medical doctors or speech therapists. 
It does not require sedation, and skilled hands can perform TFL with little discomfort 
and at no risk. TFL is "the gold standard" to visualize abnormal laryngeal 
movements.68,178-184  
In addition to playing an important role in the otolaryngological examinations, TFL 
has allowed for development of several functional tests in which its use plays a 
primary role.184 One of these is flexible endoscopic evaluation of swallowing; the 
laryngoscope is used to visualize the mechanics and efficiency of swallowing and to 
detect laryngeal malfunction and aspiration.185,186 TFL is also used to diagnose 
exercise induced laryngeal obstruction (EILO), applied in the continuous 
laryngoscopy exercise test. This method was developed at our hospital, and is suitable 
for children as well as adults.68,182,183 TFL has not routinely been used in ALS, but 
some studies have reported on vocal cord function during simple tasks such as 
vocalizing, spontaneous coughing, forced exhalation or swallowing.39,76,78,80,87,90,187,188  
 
We hypothesized that visualizing the larynx by means of video recorded TFL applied 
during ongoing MI-E in patients with ALS could contribute to a better understanding 
of the functional role played by the larynx in this contextual setting. The ultimate aim 
of this project was to apply this knowledge to improve the clinical management of 
impaired airway secretion clearance in patients with ALS. 
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3. Aims of the thesis 
The overall aim of this study was to explore the laryngeal response pattern(s) to 
mechanically assisted cough when applied in patients with ALS of different 
phenotypes and during the expected and rapidly progressing clinical course of the 
disease. Secondly, we aimed to use this knowledge to tentatively improve and 
possibly extend the use of MI-E in deteriorating patients with progressing ALS.  
 
 
STUDY #I (Paper #I) 
AIMS: To investigate the feasibility of TFL applied during ongoing MI-E, and to 
describe normal laryngeal response pattern(s) to MI-E, in healthy subjects. 
Research question #1:  
Can TFL successfully be performed during ongoing MI-E in healthy 
subjects?  
Research question #2:  
Are the laryngeal response patterns to MI-E in healthy subjects compatible to 
the laryngeal movements that are described for normal cough? 
 
 
STUDY #II (Paper #II) 
AIMS: To investigate the feasibility of TFL applied during ongoing MI-E, and to 
describe laryngeal response pattern(s) to MI-E in a cross-sectional study of patients 
with ALS of different phenotypes and to compare with healthy controls matched for 
age and gender. 
Research question #3:  




Research question #4:  
Do the laryngeal response patterns to MI-E vary between patients with ALS 
with and without involvement of bulbar innervated muscle function and when 
compared to healthy controls? 
 
 
STUDY #III (Paper #III) 
AIMS: To investigate the feasibility of TFL applied during ongoing MI-E, and to 
describe changes of the laryngeal response pattern(s) to MI-E, in a longitudinal 
follow-up study of patients with progressing ALS, and to explore if treatment 
efficacy can be modulated and improved in these patients. 
Research question #5:  
Can TFL be performed during ongoing MI-E in deteriorating patients with 
progressing ALS? 
Research question #6:  
Do the laryngeal response patterns to MI-E evolve in ALS disease 
progression? 
Research question #7: 
Can the laryngeal response patterns to MI-E be modulated and improved by 
optimizing pressure settings, flow rates and time intervals? 
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4. Material and methods 
4.1 Study design  
This was a combined cross-sectional and longitudinal observational descriptive and 
explorative cohort design, applied in a field of medicine not previously studied with 
verifiable and objective methods.  
 
Study #I (Paper #I)  
A cross-sectional study of healthy volunteers. 
 
Study #II (Paper #II)  
A cross-sectional study of ALS patients and their age-and gender matched controls. 
 
Study #III (Paper #III)  
A prospective longitudinal cohort study of ALS patients. 
4.2 Ethics 
The study was based on voluntary participation and the subjects could withdraw from 
the study at any time. Written informed consent (Appendix 1 and 2) was obtained 
from all participants. The ethical considerations that were made when planning and 
conducting this study were based on the Declaration of Helsinki.189 The study 
protocol was approved in 2011 by the Regional Committee for Medical Research 
Ethics of Western Norway (2011/784/REK vest).  
Two years after the data collection had started, a new MI-E device was launched on 
the Norwegian marked with new options for pressure, flow rate, time and oscillation 
settings. We reasoned that it would be relevant to explore, within the frames of the 




as this new MI-E device was made available by the Norwegian public health care 
system for home treatment of eligible ALS patients comparable to the enrolled 
patients. Therefore, based on the findings made in the second and cross-sectional 
phase of the project, a protocol amendment was made in 2013 to include additional 
and explorative use of MI-E settings thought to be beneficial to individual patients, 
applying to the third and longitudinal phase of the project. This protocol amendment 
was approved by the Regional Committee for Medical Research Ethics of Western 
Norway in 2013.  
4.3 Sample size 
Explorative studies have no a priori hypothesis (to be tested), but subsidiary 
hypothesis (to be explored), and calculation of sample size and final number of 
patients who should be included is difficult.190,191 ALS is relatively rare and 100% 
fatal, and all diagnosed patients living in the area served by Haukeland University 
Hospital are routinely referred for followed-up at the hospital out-patient clinic. This 
setting enabled a population-based cohort design; cross-sectional in Study #II and 
longitudinal in Study #III. Same amount of healthy control subjects, individually 
matched for age and gender were recruited for Study #II. 
4.4 Exclusion criteria 
Prior to inclusion, all participants were screened for the following exclusion criteria: 
Age < 18 years, a history of laryngospasm, sensitisation to Xylocain® (anaesthetic 
used during laryngoscopy), pneumothorax, additional lung disease, cancer, acute 
infection of the chest one month before enrolment, frontotemporal paresis with 
cognitive changes and mental instability. 
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4.5 Participants 
The thesis included three groups of participants who are described in Table 1. 
Table 1. Overview of the study participants, design and publications. 
4.5.1 Healthy medical students 
Study #I included 20 healthy medical students, recruited to demonstrate the feasibility 
of TFL during MI-E, and to describe normal laryngeal response patterns to MI-E. 
Third year students at the Medical Faculty in University of Bergen, Norway received 
both verbal and written information about the study. Twenty students entered the 
study, after having signed the consent form. 
4.5.2 ALS patients  
Population 
The participating patients were recruited from the multidisciplinary and 
multispecialized team at the ALS outpatient clinic at Haukeland University Hospital, 
which serves a population of approximately 500 000 inhabitants. We aimed to 
include as many ALS patients as possible during the 1.5-year recruitment period from 
December 2011 to June 2013, thus aiming to produce population-based data with low 
attrition rates. Approximately 20 ALS patients who have not undergone tracheostomy 
are usually enrolled at all times, and by experience approximately eight new patients 
are expected to be enrolled per year. All patients enrolled at the clinic are routinely 
rescheduled every three to six months. The patients who were enrolled at the clinic 
when the study was commenced had different disease phenotypes (i.e. both limb and 
bulbar onset) and they were all at variable stages of their disease progress.  
 Population Study design Publications 
Study #I 20 healthy medical students Cross-sectional Paper #I 




Study #II 20 healthy volunteers (controls), matched 
for age and gender with the  ALS patients 
 





At the start of this study (December 2011) and during the 1.5 years inclusion period 
37 patients without exclusion criteria received both verbal and written information 
about the study and were then invited to participate. Thirteen patients declined 
participation and four died soon after being invited, leaving 20 patients consenting to 
participate. Reasons for non-participation were severe disease and/or fatigue (n=7), or 
limb-onset ALS without bulbar symptoms and, therefore, no interest in participation 
(n=6) since treatment failure of MI-E in bulbar ALS was the focus of the study.  
Study #III 
All 20 patients from Study #II were asked to participate in the Study #III and 18 
consented. One patient did not want to be examined further due to discomfort during 
the examination procedures, and one declined due to fatigue with disease progression. 
However, shortly after inclusion in Study #III, two patients became tracheotomised 
and three died. This resulted in a cohort of 13 ALS patients having repeated and 
scheduled examinations approximately every three to six months at the ALS 
outpatient clinic during the study period from 2011 to 2016. Patients were followed 
up until death, tracheostomy or they had become too weak to come to the out-patient 
clinic, or did no longer wish to participate. 
4.5.3 Neurologically healthy age- and sex-matched controls 
A separate control group, different from the one that was recruited for Study #I, and 
instead matched for age and gender to the participating ALS patients, had to be 
recruited for Study #II. The reason was that anatomical and physiological conditions 
change with age, and that data suggest that many factors affect the function of the 
larynx change after the age of 60.192,193 Thus, 20 healthy individuals of comparable 
age and matched for gender to the participating ALS population were recruited 
through the network of our research group. 
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4.6 Study procedures 
All the examinations (Table 2) were performed in conjunction to scheduled visits at 
the ALS outpatient clinic. In the Studies #I and #II, the data was obtained during one 
pre-planned visit. In Study #III, all data retrieval was performed longitudinally at 
planned visits to the out-patient clinic until death, tracheostomy, or withdrawal. 
 









Video recorded transnasal fiberoptic laryngoscopy during: x x x 
  -Pre-set standardized protocol of MI-E settings used clinically x x x 
  -Additional use of MI-E with new modalities using individualised 
patients settings for home treatment  
  x 
Forced spirometry x x  
Slow vital capacity   x x 
Peak cough flow  x x x 
Respiratory muscle strength x x x 
Maximal insufflation capacity  x x 
Clinical neurological examination  x x 
ALSFRS-r  x x 
Assessment of dysphagia  x x 
MI-E=mechanical insufflation-exsufflation, ALSFRS-r= ALS Functional 
Rating Scale –revised 
4.6.1 Transnasal  fiberoptic laryngoscopy examination 
Transnasal fiberoptic laryngoscopy examinations were video-recorded in order to 
visualize the larynx during the use of MI-E and to provide opportunity to observe and 
describe laryngeal movements and patency retrospectively and in detail, both in real 
time and in slow motion. 
Preparations and implementation 
Participants were verbally informed about the examination both prior to the 
examination and during the complete MI-E protocol. Regular decongestant nasal 




to facilitate the introduction of the laryngoscope. Examinations were performed by 
medical doctors specialized to perform TFL examinations; i.e. either ENT surgeons 
or trained pediatricians. 
The flexible laryngoscope (Olympus ENF-P3, Tokyo, Japan), diameter 3.5 mm, was 
lubricated with local anesthetic gel (Xylocain®, Astra Zeneca, Södertälje, Sweden) 
and led through an oronasal mask, the nose and via the nasopharynx advanced until a 
good view of the larynx was obtained. A modified oronasal facemask (adult facemask 
for Cough Assist ventilatory circuit, Respironics, Murrysville, USA) served to 
fasten the laryngoscope and to allow TFL video recordings to be obtained at the same 
time as the MI-E procedures were performed. In Study #I, the laryngoscope was 
attached to a head mount with a customized scope-holder during the examinations 
(Figure 5). In the Studies #II and #III, the laryngoscope was supported manually 
(Figure 6), instead of using the customized headgear. 
The laryngoscope was connected to a video camera-system for continuous recording 
during the entire examination. The examinations were continuously filmed by two 
independent video cameras/recording systems:  
 An endoscopic video camera system (Telecam, Karl Storz, Tuttlingen, 
Germany) via the transnasal fiberoptic laryngoscopy. 
 An external video camera with an attached microphone, in order to 
document the MI-E control panel, the instructions given by the therapist, 
and the respiratory sounds produced by the patients. 
The two video recordings and the sound track were stored as one file, which allowed 
for retrospective investigation of the laryngeal events during all MI-E pressure cycles. 
To ensure adequate technical quality of the recordings while they were performed, 
the complete set-up was shown real-time during the entire procedure on a television 
screen present in the same room as the procedure was performed (Figure 6; Samsung 
Electronics 55”, Suwon, South Korea). 
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Figure 5. The set up in Study #I with laryngoscope going through a 
modified interface and attached to a custom made headset. 
 
Figure 6. The setup in Studies #II and #III with a laryngoscope passing 
through a modified interface with the laryngoscope supported and adjusted 
manually. Situation arranged. 
Standardized MI-E protocol during TFL examination 
A standardized MI-E protocol was prepared, consistent with procedures commonly 
applied during therapeutic use in patients with neuromuscular disorders with a 




automatic mode with applied mechanical insufflations and exsufflations (MI-E), and 
in a manual mode for applied mechanical insufflations (MI) only, followed by a 
manually assisted cough; i.e. thoracic thrusts applied by the therapist accompanied by 
instructions to cough. The automatic MI-E mode had the following settings: 
insufflation time of two seconds, exsufflation time of two seconds and pause time 
(between exsufflation and next insufflation) of one second. The protocol included 12 
intervention arms, i.e. various combinations of pressures, patient instructions and 
manual thoracic thrusts (Table 3). Pressures of ± 20, ±30, ±40 and ±50 cmH20 were 
used with instructions as follows. 
1) With MI-E; Instruction to actively "inhale" (but not too deep) when insufflation 
was started and instruction to actively "exhale" when the device switched to 
exsufflation.  
2) With MI-E; Instruction to actively "inhale" (but not too deep) when insufflation 
was started and instruction to actively "cough" when the device switched to 
exsufflation.  
3) With MI: Instruction to actively "inhale" (but not too deep) when insufflation was 
started and instruction to actively "cough" while subjects received manually assisted 
thoracic thrust. 
Each intervention arm was repeated two to five times to secure good quality video 
recordings. After each intervention arm, a quick break was held to prevent 
hyperventilation. In the case of patient discomfort, the procedure was stopped and 
higher examination pressures were not applied.  
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Pressure settings (cmH2O): 
MI-E           MI 
 Instruction during exsufflation: 
active exhale   active cough 
Manual  
thoracic thrust 
1. ±20  x   
2. ±20   x  
3.  +20  x x 
4. ±30  x   
5. ±30   x  
6.  +30  x x 
7. ±40  x   
8. ±40   x  
9.  +40  x x 
10. ±50  x   
11. ±50   x  
12.  +50  x x 
MI-E=Mechanical insufflation-exsufflation, MI=Mechanical insufflation. 
Intervention arms 1-12: respective pressures of MI-E or MI combined with 
instruction to either actively exhale or to cough during exsufflation. 
Additional manual thoracic thrust during cough was provided in combination 
with MI.  
Additional MI-E use of individually titrated settings 
New and individually customized MI-E settings were put into use for home treatment 
of ALS when a new MI-E device with new modalities became available on the 
market in 2013 (Cough Assist E70; Respironics, Murrysville, PA, USA). Thus, we 
additionally tested these settings as an extended study arm of Study #III.  
We tested patient triggered insufflation (on/off) and oscillation (frequency in the 
range of 5 to 10 Hz and amplitude in the range of 5 and 10 cmH2O) along with 
asymmetric use of pressure settings (positive pressure range +15 to +40 cmH2O 
combined with the negative pressure range of -30 to -40 cmH2O) and reduced 
insufflation flow (high, medium and low). Each individual setting of interest was 
performed two to four times; whereof the cycle with best quality was studied 
retrospectively for laryngeal responses. Table 4 illustrates the overview of 





Table 4. New and individually adjusted settings were put into use for ALS home 
treatment when a new MI-E device became available in 2013 (Cough Assist E70; 
Respironics, Murrysville, PA, USA), and tested as an extended arm of Study #III  
 Case no. 
 2 3 5 6 7 13 
Patient triggered insufflation (On/Off) On and off On and off On and off On and off On and off On and off 
Insufflation pressure (cmH2O) +15 to 40 +25 to 40 +20 to 40 +25 to 40 +25 to 40 0 to 40 
Insufflation flow (L/M/H) L/H L/M/H L/H M/H L/M/H M 
Insufflation time (sec) 2.0 to 3.5 1.8 to 3.0 2.0 to 3.0 2.0 2.0 to 3.0 2.0 
Exsufflation pressure (cmH2O) -40 -30 to 40 -40 -40 -35 to 40 -40 
Exsufflation time (sec) 1.0 to 2.0 1.8 to 2.0 1.7 to 2.0 2.0 2.0 2.0 
Oscillation (On/Off) Off On/off On/off On/off On/off Off 
Frequency (Hz) - 10 5 and 10 10 10 - 
Amplitude (cmH2O) - 10 5 and 10 10 5 - 
Visits with CAE70 during TFL 










L=low, M=medium, H=high 
4.6.2 Examination of pulmonary function and respiratory muscle 
strength 
Pulmonary function and respiratory muscle strength were determined as baseline 
characteristics of all study participants, and were followed up during the disease 
progression of the ALS patients participating in Study #III.  
Forced spirometry 
Forced spirometry was performed in Study #I and #II. In Study #I, it was performed 
seated and in Study #II both seated and supine, starting at total lung capacity, and 
measured with Vmax 22 (SensorMedics, Yorba Linda, USA), applying standard 
quality criteria. Forced vital capacity (FVC), forced expiratory volume in the first 
second (FEV1) and peak expiratory flow (PEF) were recorded, and the values 
expressed as percentages of predicted.140,194-197 
Slow vital capacity  
Slow vital capacity (SVC) was measured in Study #II and #III, starting at total lung 
capacity, and in seated position using a Respirometer Wright 14 (nSpire Health, 
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Hertford, UK). The highest value of three or more attempts was chosen for analysis 
and standardized to percentages predicted. 
Peak cough flow 
Peak cough flow (PCF) was measured in all studies, starting at total lung capacity, 
and in seated position via a mask using a hand-held Peak Flow Meter (Vitalograph, 
Ennis, Ireland). The highest value of three or more attempts was chosen for analysis. 
Respiratory muscle strength 
Plateau values (average of one second) of the maximal inspiratory (Pimax) and 
expiratory (Pemax) muscle strength were measured in all studies, and sniff nasal 
inspiratory pressure (SNIP) was measured in Study #II and #III, in seated position 
using a Respiratory Pressure Meter (Micro RPM; Micro Medical, Rochester, UK). 
SNIP was measured at functional residual capacity, Pimax at residual volume and 
Pemax at total lung capacity. The highest value of three or more attempts was chosen 
for Pimax and Pemax measurements, while the highest value of ten attempts was chosen 
for SNIP; and finally all raw data was standardized to percentages predicted. 
Maximal insufflation capacity 
Maximal insufflation capacity (MIC) was measured via an oronasal mask and in 
seated position using a Respirometer Wright 14 (nSpire Health, Hertford, UK) in 
ALS patients in Study #II and Study #III. MIC was measured after air stacking; i.e. 
the patient taking a deep breath, holding it, and then consecutively delivering 
volumes of air from a manual resuscitator (Lærdal Medical, Lærdal, Norway) to the 
maximum volume that the patient could hold with a closed glottis. The patient then 
exhaled the maximally held volume of air into the respirometer for volume 
measurement. The difference between MIC and SVC was calculated (MIC>SCV). 




4.6.3 Neurological assessments 
Neurological assessments were used to determine the baseline characteristics and the 
phenotype of the ALS patients when entering Study #I, and during the follow-up 
performed during Study #III.  
Clinical neurological examination and categorization 
ALS was diagnosed by neurologists in accordance with revised El Escorial 
criteria.14,15 Details on diagnostics and description of symptoms and signs and their 
onset were obtained retrospectively from medical journals. The clinical neurological 
examination included identification of the relevant symptoms and signs when patients 
were enrolled and at each subsequent visit during the follow-up period. Particularly, 
the patients were phenotyped as regards presence or absence of upper and lower 
motor neuron degeneration, or if a combination of these features were present (Table 
5).  
In Study #II, patients were categorized by the state of the disease at enrollment 
(Table 6) classified as either spinal ALS or bulbar ALS that was further sub-classified 
as progressive bulbar palsy or ALS with pseudobulbar palsy.  
In Study #III, patients were categorized in two groups by the initial onset of the 
symptoms of ALS; i.e. spinal or bulbar onset (Table 7). This data was collected either 
retrospectively from medical charts in those participants who had already been 
diagnosed and enrolled in the ALS outpatient clinic when the study was commenced, 
or at the time of being diagnosed for those who were included later. Bulbar symptoms 
were further classified as progressive bulbar palsy or pseudobulbar palsy, as 
described in Table 6.  
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Table 5. Patient characteristics used to determine bulbar upper or lower motor neuron 
involvement. 
 YES NO Notice 
Triggered jaw reflex?    
Tongue atrophy?    
Reduced force in the tongue?    
Reduced pace in the tongue?    
Considering the state of the disease  
essentially as: 
   
  Spastic (pseudobulbar paresis)    
  Peripheral (progressive bulbar paresis)    
 
Table 6. Categorization of the state of the disease at enrolment in the Study #II.  
State of the disease Symptoms and signs 
Spinal ALS Symptoms affects the limbs 
 
ALS with 
Progressive bulbar palsy 
 
Hypotonic bulbar symptoms with dysarthria  
Tongue atrophy  





Spastic bulbar symptoms with dysarthria  
No tongue atrophy  
Exaggerated jaw reflex 
 
Table 7. Categorization of the onset of the disease retrospective from medical 
journals in the Study #III. 
Onset of the disease Symptom onset in Signs 




Bulbar innervated muscles 
 
Voice harshness, defects of articulation, 
breathlessness, dysphonia, hyper nasality and 
swallowing difficulties 
 
ALS Functional Rating Scale-r (ALSFRS-r) 
Patients were assessed by the neurologists using the ALS Functional Rating Scale 
(ALSFRS-r). The ALSFRS-r is a validated measure of functional impairment in 
ALS,198 nevertheless its sensitivity is discussed.199 It is a questionnaire-based 




function) to 4 (normal function), divided into 3 sub scores (bulbar 12, spinal 24, and 
respiratory 12), with normal function defined by a maximum score of 48.198 
Items from the ALSFRS-r involving functions of speech and swallowing (maximum 
score of 8) were used to rate the bulbar impairment scale (BIS) in Study #II. 200 
In Study #III the bulbar and respiratory scores were calculated from ALSFRS-r, 
where the items of speech, salivation and swallowing, dyspnoea, orthopnoea and 
ventilation were calculated (each with a maximum score of 12).198 
Assessment of dysphagia 
Dysphagia in Studies #II and #III was determined with 100-ml water swallow test 
(WST). Subjects were asked to drink 100-ml water and the timing (seconds) to 
complete the task was recorded. Swallowing speed  < 10 ml/s was classified as 
dysphagia.201,202 
4.7 Analysis of the videorecordings 
4.7.1 Editing of the video clips 
Video recordings from each subject were edited into a video file including film clips 
based on representative shots of each intervention arm. In the video evaluation, the 
MI-E cycles were cut into three phases of interest: the insufflation phase, the point 
when the MI-E device switches from positive to negative pressure (labelled the 
pressure drop), and the exsufflation phase or the voluntary cough with no negative 
pressure applied. The onset and offset of each phase was observed and defined from 
the parallel external video recording of the MI-E manometer (Table 8).  
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Table 8. Definitions for onsets and offsets of phases for insufflation, pressure drop, 
exsufflation and voluntary cough with no applied negative pressures 
Phase of interest Definition for onset  Definition for offset 
Insufflation  
(Time settings  
for insufflation is 2 seconds) 
The point when the positive 
pressure is started with the MI-E 
device. Observed from the 
manometer on the control panel of 
the MI-E device. 
Offsets when the positive 
pressure on manometer turns 
off. 
Pressure drop  
(Automatically very rapid phase) 
The point when the MI-E device 
switches from positive to negative 
pressure. Observed from the 
manometer on the control panel of 
the MI-E device. 
Offsets when the negative 
pressure commences and 
appears on the manometer on 
MI-E devices control panel. 
Exsufflation  
(Time settings  
for exsufflation is 2 seconds) 
The point when the negative 
pressure is applied with the MI-E 
device. Observed from the 
manometer on the control panel of 
the MI-E device. 
Offsets when the negative 
pressure on manometer turns 
off. 
Voluntary cough with no applied 
negative pressures 
The point when the MI-E device 
has pressure of zero after an 
insufflation. Observed from the 
manometer on the control panel of 
the MI-E device. 
Offsets when the last glottic 
closure in voluntary cough 
maneuver is observed. 
4.7.2 Interpretation of the video clips 
Since the laryngeal movements during MI-E have not been studied previously, there 
was no standardized assessment score available. The intention of the present study 
was to establish a scientific foundation and a tool for the assessment of the larynx 
during MI-E. Laryngeal movements were observed and assessed from the video files, 
and this process generated categorized data from these explorative examinations. 
Laryngeal anatomy and movements at rest in Study #I and #II were evaluated by a 
senior otolaryngologist. Laryngeal responses during MI-E were evaluated by this 
PhD candidate in cooperation with a senior otolaryngologist. In Study #II recordings 
were initially evaluated together by two raters (Anne-Kristine Brekka, MSc student in 
cardiopulmonary physiotherapy, and this PhD candidate) and verified by a senior 
otolaryngologist.  
The video clips were reviewed and evaluated both in real time and in slow motion as 
many times as needed, both in real time and in slow motion. The observed 




described both by words and with snapshots of the laryngeal positions during the 
movements. Thereby laryngeal responses were classified into explicitly defined 
categories, and an observation scheme was prepared (Appendix 3). Thereafter the 
video recordings were replayed as many times as needed and the responses observed 
in the individual participants were assessed and recorded by “yes or no” in the 
observation scheme. Laryngeal responses during MI-E were compared to “adequate 
laryngeal control”, defined as described for normal cough in the literature,65,67 and 
presented as initial inspiratory abduction of the true vocal folds and aryepiglottic 
folds, and thereafter glottic closure with subsequent rapid opening when coughing, 
abduction of the true vocal folds and aryepiglottic folds followed by sequential 
closures and/or narrowing in the exhalation phase of the cough.  
In the Study #III, five laryngeal events were targeted and tested, and defined as 
adverse and typical “bulbar features” and depicted in Table 9. See Figure 8 for the 
process chart. 
 
Figure 7. The examinations were recorded using two continuously running 
and synchronised video streams on one screen, depicting the laryngeal 
view in one and the various phases on the MI-E device in the other. 
Anatomic landmarks are illustrated on the laryngeal top view. 
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Table 9. Five laryngeal events during MI-E defined as adverse and typical bulbar 
features based on findings in Study #II, contrasting what has been described as 
normal cough.65,67 
Laryngeal level Adverse laryngeal response during MI-E 
Glottic True vocal 
folds 
Adduction of true vocal folds during insufflation; 
paradoxical movement of true vocal folds during 
inhalation creating either a slim glottic opening or a total 




Medial rotation of the cuneiform tubercles accompanied 
by considerable adduction of aryepiglottic folds during 
insufflation, to the extent that it prevents observation of 
the glottic laryngeal level below. 
 
 Epiglottis A retroflex movement of the epiglottis (a passive dorsal 
rotation) covering the glottis, either as a brief movement 
or lasting throughout the insufflation. 
 
Hypopharyngeal Tongue base Backward movement of the tongue base during 
insufflation constricting the laryngeal entrance. 
 
 






Figure 8. Process chart of analysing the laryngeal responses during MI-E 




4.8 Statistical methods 
The statistical analyses used in all studies are presented in Table 10. All p-values 
were two-sided and values below 0.05 were considered statistically significant. 
 
Table 10. Statistical methods used in Studies #I to #III. 






Group counts and frequencies x x x 
Mean and standard deviation x x x 
Median and range   x 
The chi-square test or Fisher’s exact test if expected cell counts < 5  x  
Depicted line plots of longitudinal continuous measures   x 
Kaplan Meier survival function   x 
Log rank test   x 
Wilcoxon Signed Rank test   x 
 
Study #I 
Quantitative data of laryngeal movements during the MI-E were presented as 
percentages with the described movements. Baseline characteristics were presented as 
descriptive statistics in tables with means and standard deviations. Data from the 
assessment were processed in Excel for Windows Office version 2010 (Microsoft, 
Redmond, Washington, USA) and in SPSS v18.0 (Statistical Package for Social 
Sciences, SPSS Inc, Chicago, Illinois, USA). 
Study #II 
The number of subjects with the described patterns of laryngeal movements during 
MI-E was given as group counts and percentages. The chi-square test, or Fisher’s 
exact test if expected cell counts were less than five, were applied to assess 
differences between groups with regard to categorical data. Background data were 
given as group means with standard deviations. Statistical analyses were conducted 
using SPSS v21.0 (Statistical Package for Social Sciences, SPSS Inc, Chicago, 
Illinois, USA).  
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Study #III 
The number of subjects with the described patterns of laryngeal movements during 
MI-E was given as group counts. Individual longitudinal continuous measures were 
depicted using line plots. The Kaplan Meier survivor function was used to estimate 
the proportion of the various clinical and MI-E events as well as the corresponding 
median event times. To test for difference in survival functions across groups, the 
log-rank test was used. In the Kaplan Meier analyses, the time (in months) from ALS 
symptom start until the first occurrence of the relevant event was used as the measure 
of event time. A person’s event time was "right censored" if he died or did not 
experience the event before study end, defined as December 31st 2016. To investigate 
if various laryngeal outcomes occurred before the onset of bulbar symptoms in time, 
we used Wilcoxon Signed Rank test. If an individual did not experience laryngeal 
events and/or bulbar symptoms, that individual was removed from the analysis. 
Patient group characteristics were quantified, and central tendencies given as means 
or medians with variability measures indicated by standard deviation, 95% 
confidence intervals, or range, as appropriate. All statistical analyses were performed 




5. Summary of results 
Background characteristics of the study participants (n=60) are described in Table 
11, and the overview of the scheduled intervention arms and evaluated video clips of 
TFL examinations is presented in Table 12. 
 
Table 11. Background characteristics of the study participants (n=60). Figures are 
group means with standard deviations.   
 Healthy  
medical students  
(n=20) 
Healthy  
age- and gender 
matched controls 
(n=20) 
ALS patients in 
the cross sectional 
study 
(n=20) 
ALS patients in 
the cohort study 
(n=13) 
Male/female ratio 8/12 13/7 13/7 10/3 
Age, years 24.4 (1.9) 66.9 (7.2) 68.7 (9.3) 67.1 (8.5) 
BMI, kg/m2 22.6 (2.0) 23.9 (2.4) 23.6 (4.3) 24.1 (3.4) 
FVC, % pred 106.7 (8.5) 113.6 (16.0) 67.4 (22.1) 72.4 (18.7) 
FEV1, % pred 99.1 (13.0) 107.4 (19.0) 70.6 (25.7) 74.5 (25.0) 
SVC, l - 4.15 (1.3) 2.92 (1.0) 3.4 (0.7) 
SVC, % pred - 110.6 (20.1) 76.1 (22.5) 82.5 (15.7) 
PCF, l/min 501.0 (100.7) 484.5 (130.2) 266.8 (145.8) 318.5 (128.6) 
Pimax, cmH2O 101.0 (23.9) 95.2 (23.6) 43.3 (20.9) 49.3 (20.5) 
Pimax, % pred 101.0 (24.3) 111.3 (24.9) 52.9 (23.7) 57.3 (19.5) 
Pemax, cmH2O 132.6 (28.3) 140.8 (37.9) 50.4 (30.0) 61.2 (31.1) 
Pemax, % pred 105.1 (20.3) 140.1 (34.3) 49.4 (24.8) 56.3 (25.3) 
SNIP, cmH2O - 91.2 (33.7) 38.6 (17.9) 42.0 (17.9) 
SNIP, % pred - 99.1 (34.6) 42.6 (19.0) 45.2 (20.0) 
MIC>SVC, l - - - 0.26 (0.44) 
WST, ml/s - 31.50 (7.7) 12.3 (11.4) 16.3 (11.0) 
ALSFRS-r - - 36.7 (8.4) 38.5 (5.9) 
BIS - - 6.0 (2.3) 6.38 (2.1) 
BS - - 8.79 (3.9) 9.5 (3.1) 
RS - - 9.95 (3.4) 10.2 (3.1) 
ALS=amyotrophic lateral sclerosis, BMI=body mass index, FVC=forced vital 
capacity, FEV1=forced expiratory volume in 1 second, SVC=slow vital 
capacity, PCF=peak cough flow, Pimax=maximal inspiratory mouth pressure, 
Pemax=maximal expiratory mouth pressure, SNIP=sniff nasal inspiratory 
pressure,  MIC=maximal insufflation capacity, WST=water swallow test, 
ALSFRS-r=ALS functional rating scale (revised), BIS=bulbar impairment 
scale, BS=bulbar score, RS=respiratory score 
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percent (%)  
Study #I 240 239 1 0.4 
Study #II 480 453 6 1.3 
Study #III 763 751 12 1.6 
Total in all studies 1483 1443 19 1.3 
 
5.1 Paper #I (Study #I) 
Laryngeal Response Patterns to Mechanical Insufflation-Exsufflation in Healthy 
Subjects 
All participants (20 healthy volunteers, aged 21-29 years) completed all examinations 
according to plan. Visualization of the larynx with TFL did provide a good overview 
of the larynx, and it was possible to observe movements of the laryngeal structures 
throughout the complete MI-E intervention. In total 239 laryngoscopy recordings 
were analysed.  
An initial abduction of the vocal folds was observed in all subjects, both during the 
insufflation and exsufflation phases. 19 of 20 subjects adequately coordinated glottic 
closure when instructed to cough. When instructed simply to exhale during 
exsufflation, the glottis stayed open in a majority. Subsequent to an initial abduction 
during exsufflation and cough, various obstructive laryngeal movements were 
observed in some subjects, such as narrowing of the true vocal folds, retroflexion of 
the epiglottis, hypopharyngeal constriction and backward movement of the base of 
the tongue. 
In conclusion, the study showed us that video recorded TFL during MI-E was 
possible in healthy subjects, and also a feasible and well-tolerated method to 
characterize laryngeal movements. The laryngeal responses to MI-E were compatible 




were some heterogeneities. The findings from the study suggested that laryngoscopy 
may be of value in patients.   
5.2 Paper #II (Study #II) 
Laryngeal response patterns influence the efficacy of mechanical assisted cough in 
amyotrophic lateral sclerosis 
All 20 patients with ALS (6 without bulbar symptoms and14 with bulbar symptoms; 
7 with pseudobulbar palsy and 7 with progressive bulbar palsy) and 20 neurologically 
healthy controls, matched for gender and age, were tested. Four patients with bulbar 
symptoms completed only parts of the MI-E protocol due to discomfort from the 
applied pressures. In total 453 (94%) of 480 scheduled recordings were analyzed. The 
overall impression was that video-recorded TFL was a tolerable and feasible method 
to characterize laryngeal responses throughout MI-E in ALS patients. 
In general, the larynx moved downwards during applied insufflation and upwards 
(cranially) during exsufflation. Healthy subjects and patients with ALS and no bulbar 
symptoms (n=6) coordinated their cough well during MI-E. The ALS patients with 
bulbar symptoms (n=14) adducted their aryepiglottic folds (supraglottic level) during 
insufflation. At the glottic level, initial abduction of true vocal folds followed by 
subsequent adduction was observed in all ALS patients (n=20) during insufflation 
and exsufflation. Hypopharyngeal constriction during exsufflation was observed in all 
subjects, most prominently in patients with ALS and bulbar symptoms. Differences in 
laryngeal movements between patients with pseudobulbar (n=7) and progressive 
bulbar ALS (n=7) were not statistically significant. 
In conclusion, the study showed that laryngoscopy during ongoing MI-E was possible 
in patients with ALS. If bulbar symptoms were present, the larynx adducted, 
especially during insufflation but also during exsufflation, severely compromising the 
size of the laryngeal inlet in some. This effect seemed to be influenced by the MI-E 
settings in that higher pressures had a greater negative impact.  
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5.3 Paper #III (Study #III) 
Mechanically Assisted Cough in Progressing Amyotrophic Lateral Sclerosis 
The 13 ALS patients who were longitudinally followed up varied substantially 
according to ALS subtype and disease progression. Follow-up time was median 17 
months (range 6-59). In total 751 TFL recordings from 67 individual examinations 
were analyzed (per patient median 4, range 2-11).  
The following adverse laryngeal events developed with disease progression during 
insufflation: Adduction of aryepiglotic folds was observed in all patients, initially at 
the highest positive pressure (50 cmH2O) and prior to onset of other bulbar symptoms 
in the majority. As cough became less expulsive with disease progression, 
aryepiglotic fold adduction occurred also at lower insufflation pressures (20 cmH2O). 
In 5 patients with spinal onset and no bulbar symptoms at study entry, aryepiglottic 
fold adduction occurred at 50 cmH2O at median (range) 38 (19-60) months after the 
ALS debut compared to 47 (30-57) months for other bulbar symptoms (p=0.046). 
Adduction of true vocal folds occurred in 8 of 9 spinal onset patients. Retroflex 
movement of the epiglottis was observed in 7 of 13 cases regardless of insufflation 
pressures and independent of bulbar involvements. Backward movement of the 
tongue base appeared regardless of insufflation pressures in all but one subject.  
During exsufflation constriction of the hypopharynx was observed in all patients 
regardless of the presence of bulbar symptoms, and appeared after the above listed 
adverse events during insufflation.  
Adverse laryngeal response patterns developed before the onset of other bulbar 
symptoms in most patients. As the disease progressed, cough at the laryngeal level 
was observed to become gradually less synchronized during the MI-E, and the 
laryngeal cough movements were observed to become rigid and require longer time. 
MI-E treatment could also be complicated by swallowing, which seemed to be 
associated with retroflex movement of epiglottis. 
Individually modified MI-E settings were explorative assessed with TFL in 6 patients 




outpatient assessments, analyzing a total of 45 film clips from altogether 19 visits. 
Customized use of MI-E, applying lower insufflation pressures and flows, were 
observed to provide less adduction in the larynx, both at the supraglottic and glottic 
level, with more appropriate laryngeal responses to insufflation at least in some 
(possibly all) cough cycles. This prolonged the time for which the treatment was 
perceived efficient by patients. The use of one cough cycle at the time, allowing for a 
‘pause’ prior to the next insufflation, and instructions to actively inhale prior to 
insufflation, was observed to induce better cough synchronization, particularly in 
cases of a retroflex epiglottis or spasticity at the laryngeal level.  
In conclusion, the study showed us that laryngoscopy during ongoing MI-E was 
possible to perform repeatedly in deteriorating patients with progressing ALS. The 
study suggested that “blindly” applying high insufflation pressures during 
mechanically assisted cough in ALS can become counterproductive during disease 




In this thesis we have demonstrated that it is possible to visualize the larynx by TFL 
during MI-E in healthy persons and in patients with ALS, and that the method was 
tolerated when applied repeatedly in deteriorating patients as their ALS progressed. 
Thus, laryngeal responses to MI-E can be observed, video-recorded and analysed 
retrospectively, allowing observation and description of dissimilarities between 
healthy subjects and ALS patients. The laryngeal responses to MI-E in patients with 
bulbar ALS differed from what we saw in healthy subjects in ways that were 
seemingly counterproductive in terms of treatment effect, and also unexpected 
compared to what has been suggested in studies performed by others.141 When 
following 13 ALS patients throughout their disease progression we saw that adverse 
and seemingly counterproductive laryngeal response patterns developed in most of 
them, and that this occurred before development of the typical “bulbar ALS 
phenotype”. The knowledge provided should be tested by others in larger studies. 
However, the findings suggest that clinical use of MI-E in ALS should be 
individualized, and if confirmed respiratory therapists will need to alter their clinical 
management of ALS patients. Our results indicate that individually tailored MI-E 
treatment can improve and possibly extend the use of non-invasive MI-E in ALS. 
In the following, methodological strengths and limitations will be discussed and 
ethical issues considered. Thereafter there will be a general discussion of the main 
findings, clinical implications and suggestions for future research. 
6.1 Methodological considerations 
6.1.1 Strengths and limitations 
The major strength of this study lies in the overall idea of filling an important 
knowledge gap that is of practical implication to a group of patients who suffer from 
a devastating, progressive and fatal disease. Thus, the study tested a novel method of 




health and disease. The method was used for comprehensive assessments during a 
wide range of MI-E settings combined with patient instructions that are regularly 
used in clinical practice. This is therefore the first study that can provide systematic 
visual information on how the larynx performs during ongoing MI-E in ALS patients, 
cross-sectionally as well as throughout their disease progression. This is an issue that 
potentially will be of great importance to these patients. The studies have engaged 
and created a multi-professional research group that has included specialists from 
otolaryngology, neurology and respiratory medical environments and respiratory 
physiotherapists. 
The participating group of ALS patients was recruited from a complete geographical 
area, and the study was thus population based by design. The patients were followed 
longitudinally for as long as possible, limited only by disadvantageous manifestations 
of their progressing disease. Healthy volunteers, matched for age and gender with the 
participating ALS patients, served as control group.   
The major weakness of the studies lies in their size; as with all small studies the 
findings must be cautiously interpreted. To some extent this uncertainty was 
compensated by the population based design and by recruitment of a highly typical 
group of ALS patients who did exhibit an expected clinical course during the study 
period. Nevertheless, the knowledge provided should be tested by others in larger 
studies. The explorative design also calls for repeated testing of the findings in other 
and unrelated but comparable patient populations. Moreover, neither intra- nor inter-
observer repeatability of the findings was tested. These are all issues that prevent firm 
conclusions being made as regards internal and external validity, to be discussed in 
details below. 
Another weakness, or rather a shortcoming, of the studies, was that we were unable to 
fully test the opportunities that lie within the options provided by the new technology 
becoming available in a rapidly developing market. Thus, this research field is still in 
its "embryonic" phase. 
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6.1.2 Study design  
As current knowledge in this field is sparse, an explorative approach was chosen. A 
prospective observational descriptive design allowed observation - and thereby 
description - of hitherto unknown responses.  
Cross-sectional study design (Study #I and #II) 
This type of study design is used to document a status at a single time point for each 
participant within the study. Additionally, Study #II included a matched control 
group, suitable to compare the outcomes and the characteristics of the enrolled 
population based patient group.203 The cross-sectional study design does have 
limitations, especially when examining patients with a progressive disease like ALS; 
the patient is examined at one time point, acknowledging that the results obtained 
might differ from results obtained at another time point.203 This will influence the 
results, as it is practically not possible to compare patients at different stages of their 
disease progression at exactly the same phase. Nevertheless, the cross-sectional study 
design allowed for an overall assessment of the feasibility of the method in this 
patient group, and also for a description of laryngeal response patterns to MI-E in 
ALS patients of different phenotypes and how these patterns differed from those of 
the healthy control group.  
Prospective cohort study design (Study #III) 
A gradual development of bulbar innervated muscle dysfunction has been suggested 
to influence the extent of successful use of MI-E; thus, it was important to investigate 
the long term responses in a longitudinal design. A challenge facing all longitudinal 
studies is that data must be collected over long time periods. Considering a 5-year 
survival rate for ALS of approximately 20%, the five year follow-up period of the 
present study was considered adequate.2,13 Cohort studies are suited to determine the 
natural history of a condition.203 In the present Study #III, the data retrieval could not 
be performed continuously, but at pre-set outpatient appointments. Even so, adverse 




cases without bulbar symptoms at inclusion, indicating that the findings of the study 
were solid. 
6.1.3 Subjects 
External validity is the expression used to describe the extent to which the results of a 
study can be generalized to other populations or other patients with the same 
disease.203 A population based sample implies that all participating patients with the 
disease under study are recruited from a specified population and that all patients 
with that disease and who belong to that particular population are invited to 
participate. In our studies, all patients with ALS were recruited from the area served 
by Haukeland University Hospital, and no patients with ALS who lived within that 
area remained uninvited.  
The data obtained from the ALS patients were compared with those of healthy 
matched volunteers who were recruited by a convenience sampling principle; i.e. 
drawn from a population that was easily accessible.204 The control subjects 
participating in Study #I were young medical students, individuals whose health, 
social and socioeconomic status can be assumed to be above average. The control 
subjects participating in Study #II were recruited in order to match the age and gender 
of the participating patients with ALS. Both these control groups turned out to be fit 
and with low BMI, good lung function and high respiratory strength. As such, the 
control groups of Study #I and #II can be seen as “too healthy or wealthy”, possibly 
increasing the differences versus the ALS group. However, we do not have 
information suggesting that factors such as fitness, BMI and social or socioeconomic 
status should influence laryngeal function and its responses to externally applied 
positive and negative airway pressures. 
Concerning the ALS population, their clinical disease presentation is generally highly 
heterogeneous due to variability of upper and lower motor neuron involvement, the 
disease onset and its progression. This heterogeneity was found also in our ALS 
population. Their peak cough flow values were below 270 litres/min in most of the 
 70
examinations, indicating that they represent a fairly “typical” population with ALS in 
need of MI-E to improve their airway clearance.140 There were 13 patients who 
declined and four who died soon after being invited to Study #II; a situation that can 
possibly have caused a selection bias.203 Reasons for non-participation were either 
severe disease or absence of bulbar symptoms. The critical scenario in the 
longitudinal follow-up Study #III was to obtain data also from the most severely ill 
patients. We were able to follow these patients for long periods, also in relatively 
severe distress.  
To conclude on these issues, we hold that our patient population was representative 
for ALS patients in general, and that the control groups adequately reflected the 
expected a normal responses to MI-E. 
6.1.4 Sample size 
A sufficient number of subjects and observations per subject are needed for adequate 
internal and external validity of a study.203 A sample size of 20 ALS patients in the 
cross-sectional study and 13 ALS patients in the prospective cohort study reflects the 
relatively low prevalence of ALS and the small population base from which 
participants were recruited. As this was an explorative study set up to investigate 
hitherto unknown outcome data with unknown distributions, a priori power 
calculations or sample size estimation could not be undertaken.190,191 The small size 
of the study complicated statistical handling of the data, and contributed to a situation 
were the generalizability of the results could be questioned. Particularly, these issues 
make the study vulnerable for type-II errors; i.e., failure to detect significant 
differences that may have been present.190  
The heterogeneity of our findings suggests that it can be possible that even more 
nuances or variations or other types of responses imposed by MI-E in ALS could 
have been found, had the study population been larger. However, with numerous 
observations collected from our sample of 20 ALS patients, we found a clear pattern 
of laryngeal adduction occurring during insufflation in bulbar ALS patients when 
compared to patients without bulbar symptoms as well as when compared to the 




their disease progression, as they gradually developed bulbar involvement, first at the 
highest MI-E treatment pressures, and later in their progression also at gradually 
lower pressures. Thus, as it seemed, a dose-response relationship between MI-E 
pressures and adverse laryngeal outcomes could be suspected as ALS proceeds. 
Thus, we hold it to be relatively improbable that studies of larger ALS populations or 
other control groups would have reached other conclusions than ours. However, we 
acknowledge and certainly encourage, that our findings must be systematically tested 
in other and larger ALS populations, treated and followed at larger institutions than 
ours.  
6.1.5 Visualization of the larynx 
The results of this thesis are based on the visualization of the larynx with TFL during 
MI-E. Construct validity indicates to what extent the test or instrument measures 
what it is supposed to measure,205 and refers to whether a study is able to truly answer 
the research questions.203 TFL examination is the gold standard for visualization of 
larynx.178-181,206 Several small studies have used TFL in ALS patients to describe 
laryngeal function during simple tasks.39,76,78,80,87,90,187,188 Further, patients are referred 
to otolaryngologists and examined with TFL as a part of a diagnostic work-up for 
ALS due to laryngeal symptoms.39 We used the TFL in a new setting, and 
experienced only a small amount of technical failures. Laryngeal responses and 
movements throughout the MI-E protocol were as previously described for normal 
cough in the healthy participants of Study #I,65-67 and the findings were different in 
bulbar ALS patients. We are not aware of any other and better methods that could be 
used to examine the laryngeal responses during MI-E. Only one study has previously 
explored the role of the upper airway during MI-E; i.e., Sancho et al. who performed 
an observational study of three ALS cases using CT scans and observed dynamic 
upper airway collapse during exsufflation.141 The limitations of their study are mainly 
linked to the limitations of using CT as a method to observe continuous cough cycles, 
and the fact that they did not examine the upper airways during insufflation, probably 
related to their hypothesis (i.e. upper airway collapse during the negative pressure). 
 72
Our results indicate that their study failed to reveal the complete picture of laryngeal 
responses to MI-E, as they did not focus on the inspiratory phase which is so 
important for the first phase of cough; the crucial ‘filling up’ of the lungs. Direct 
visualization of the larynx with TFL could provide a visual overview of the laryngeal 
structures throughout the complete MI-E interventions.  
The video recordings were precious parts of the diagnostic set-up. Two continuous 
videos were running in parallel, showing respectively the internal laryngoscopy 
images and the external MI-E set-up with the pressure settings, both inputs 
synchronized and showed real time on one television screen and later stored as one 
file to be showed on a computer monitor. This allowed retrospective analyses, 
enabling fine nuances and rapid movements to be visualized during slow motion and 
the findings to be validated afterwards by other observers.204,205  
Nevertheless, the examination with TFL during MI-E has limitations which can affect 
the validity of the findings. In all participants, the larynx tended to move upwards 
during the MI-E cycle, requiring adjustments of the position of the laryngoscope. In 
some subjects, anatomical characteristics could preclude visual access, such as a high 
standing epiglottis. In ALS patients we encountered additional challenges. As the 
larynx moved considerably more downwards and upwards during insufflation and 
exsufflation, dynamic adjustments of the laryngoscope position were required and the 
laryngoscopy was supported manually instead of using customized headgear as in 
Study #I. In some cases airway secretions led to poor-quality recordings and pre-
treatment aiming to clear secretions could have been considered. This was more often 
observed with disease progression in Study #III. Further, the adduction of the 
aryepiglottic folds obscured the view of the true vocal folds, and therefore the glottic 
level was not always successfully visualized. To compensate for these challenges and 
to produce adequate recordings, we repeated the MI-E cycles several times, which led 
to good quality recordings in at least one MI-E cycle per intervention in almost all 
sessions. These issues need to be considered in future studies using TFL during MI-E. 
We hold that direct clinical visualization of the larynx using TFL provides a good 




This opinion recently gained support by a study by Sayas Catalàn et al.,207 who 
postulated that titration of non-invasive ventilation (NIV) by means of visualization 
of the larynx with TFL leads to fewer obstructive events in subjects with upper-
airway obstruction. Also Georges et al.,208 inspected the larynx with TFL during NIV 
in 11 patients with ALS to increase the understanding of potentially 
counterproductive laryngeal response patterns.  
6.1.6 Interpreation of the video recordings 
There were no preexisting assessment scores that could be used directly in the 
evaluation of the video-recordings and the interpretations of the laryngeal responses 
were done by observing and describing the video-recordings which is usual in 
laryngeal inspection with TFL. This is solely an observational approach, which only 
requires a systematic knowledge of what to observe.203 The knowledge on which the 
evaluations of the present study are based, mainly rest on clinical - and research 
based activities performed by professionals who are members of our research group, 
and on the knowledge obtained from close to 2000 tests performed for exercise 
induced laryngeal obstruction (EILO).182 This work includes the EILO scoring tool, 
which has proved to be a reliable and valid tool in EILO.183 Such a specific scoring 
system cannot automatically be applied in a different disease context; however, it did 
contribute to our interpretations of the laryngeal responses to MI-E. Development of 
a scoring tool is time consuming, and combined with a low number of participating 
patients it was considered beyond the scope of the present study to establish a graded 
scoring system specifically designed to cover laryngeal responses to MI-E in ALS. 
However, in our opinion the observation scheme prepared in Study #I and further 
developed in Studies #II and #III can be used in clinical examinations with TFL 
during MI-E. Important issues like validity and reliability of this tool should be tested 
in future studies.  
Because the observer is ‘the instrument’, determining the reliability of observational 
measures is linked to determining intrarater and interrater reliability. Intrarater 
reliability could be assessed by using repeated MI-E cycles obtained from the same 
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study session, whereas interpretations of the video-recordings by different raters 
could be used to address interrater reliability. The measure is considered reliable if it 
repeatedly gives us the same result; assuming that what we are measuring is not 
changing. Repeatability is an integrated part of the validity of an assessment; a test 
can be reliable without being valid, but it must be reliable to be valid.203  
We did have the data to perform analyses of intrarater and interrater reliability, but 
these features were not formally addressed in the present studies. We interpreted the 
video-recorded data with the most reliable existing method to date; by the trained and 
experienced human eye. To secure reliable evaluations, several professionals were 
involved, working together in a consensus based approach. We acknowledge that 
other investigators could have found nuances in the laryngeal observations not 
emphasized by us. In the future, specifically designed tracking tools (algorithms to 
detect certain responses) of video recordings could theoretically be developed to 
assess the observations more objectively. Formal tests of reliability and validity 
should be performed in future studies.  
6.1.7 Functional value of the observed laryngeal closure 
Both insufflating and exsufflating the lungs require an adequately sized laryngeal 
inlet,44 and it is reasonable to assume that visually observed laryngeal adductions or 
even closures, are associated with corresponding obstructions to airflow and thus 
influence the efficiency of the MI-E treatment. However, we do not in fact know to 
what extent the laryngeal adductions observed during MI-E influences the airflow. 
This represents an important functional issue that was not addressed during the work 
with this thesis. Measurement of the airflow synchronized to the TFL examinations, 
could definitely shed light on these issues. Measurement of airflow near the facial 
mask has been used to measure upper airway obstruction during sleep, where reduced 
flow indicates upper airway obstruction.209,210 Airflow curves have been constructed 
to monitor physiological effects in studies on MI-E.119,155,211 Lacombe et al. presented 
an airflow profile curve obtained from a neuromuscular patient during coughing 
while being supported by MI-E cycles. By interpreting the flow changes on the curve, 




description of laryngeal movements is of course hypothetical since they did not 
directly observe the larynx, but relevant for our findings. Simultaneous monitoring of 
the airflow curve and visualization of the larynx during MI-E could reveal more 
information about the functional outcomes of TFL and potentially add validity to our 
results, and should be targeted in future research. We did collect data that can be used 
to construct airflow curves, but these issues were not addressed in the present studies 
but will be in the near future. 
6.2 Ethical considerations 
We need to perform clinical research in order to understand and to advance our 
management of diseases that affect quality of life, cause pain, suffering or death.212 In 
the present thesis, both the included patients (with a fatal disease) and the 
examination method (of TFL used during MI-E) requires ethical considerations.212  
6.2.1 Research projects including ALS patients 
Relevance 
ALS patients are vulnerable, facing a fatal disease which severely limits their life 
expectancy. Clinical research performed in such patients must be extraordinary well 
designed and should preferably also include elements that aim to improve the daily 
care of the participants.212  
The main focus of the present study was to improve daily respiratory care of patients 
with ALS. Accumulation of mucus without the ability to cough is a huge 
psychological burden that massively and negatively impacts quality of life. 
Additionally, it may cause pneumonia - the main cause of death in ALS. Airway 
clearance therapy with MI-E has empirically proved effective in several other 
neuromuscular disorders, however is challenging in ALS patients; therefore it was 
important to investigate these issues.  
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Informed consent 
Researchers whose study participants are terminally ill or very sick people must give 
extraordinary careful attention to the informed consent process in their research 
protocols as well as in their conduct and behaviour when interacting with eligible 
patients.212 In the present study, all eligible patients received both verbal and written 
information about the study and a signed consent was required before inclusion. 
Although ALS is a neurological disease affecting also parts of the brain, the 
intellectual capacity of those affected is not influenced, unless they have 
frontotemporal dementia which is rare and also was one of the study exclusion 
criteria.4 In the present study we carefully pointed out in a balanced way potential 
inconveniencies and disadvantages as well as potential advantages. We also 
emphasized that declining to participate would not in any way influence their 
treatment, and that knowledge gained from the study potentially could improve 
treatment, and would be made available also to them - to the extent possible. Patients 
had at least a week to think about participation, which prevented a rushed consent. 
It is our opinion that eligible patients were carefully and conscientiously approached 
and informed about the ‘pros and cons’ of participation, and that patients for whom 
participation was perceived to involve some form of extra challenge were excluded. 
Desperation and dependencies 
The project manager worked as a respiratory physiotherapist at the ALS outpatient 
clinic at study initiation, and thus had a therapist-patient relationship with several of 
the eligible patients. This raised particular issues and concerns, as eligible patients 
may have been willing to join the research project because they perceived themselves 
as being in a dependent position, they may have been extraordinary primed to 
participate, or they may have been extraordinary anxious or even desperate to have 
the best available treatment, even for a highly distant prospect of personal benefit.212 
To prevent this, we were clear that declining participation would not affect the 
regular treatment at the out-patient clinic. Still, we experienced that patients familiar 
with MI-E treatment were particularly eager to participate, similar to patients with 




expectations for own personal gains from participation were warranted.212 Prior to the 
examinations, many of the included patients expressed that if they did not get any 
direct benefit for themselves, they wanted to improve the treatment of other patients 
with the same disease. 
It turned out that patients participating in the study in fact did get individual benefits 
from the TFL examinations by more adequately and individually adjusted MI-E 
settings due to an understanding of their laryngeal responses that would not otherwise 
have been possible. Some of them also extended their use of MI-E, and potentially 
extended the use of NIV because of more successful non-invasive airway clearance.  
In retrospect, it is our overall (humble) opinion that the study subjects participated 
because of a personal interest in the topic, and that their participation resulted in 
individual benefits for most of them. The use of their ‘end-of-life time’ to take part in 
the study examinations was considered meaningful and also had a clinical benefit. 
6.2.2 Examination with TFL  
TFL is well-tolerated, though it is an invasive procedure which may feel unpleasant, 
as the laryngoscope is introduced through the nose and upper airways. Our research 
group has extensive expertise in the use of TFL in a wide variety of circumstances, 
patient and age groups, and considered participation safe with minimal risks and 
relatively few nuisances. This view was supported by the present study, in that only 
two out of 20 patients enrolled in the cross sectional Study #II actively declined to 
enrol also in the longitudinal Study #III and only one of them gave as their reason as 
‘discomfort during the examinations’. This patient expressed that the discomfort was 
mainly related to the use of MI-E, which was unfamiliar for her, and not to the TFL 
per se.  
To secure that TFL during MI-E with ALS patients was possible, we initially 
examined healthy individuals to increase our competence (Study #I). Skilled 
otolaryngologists or pediatricians who perform laryngoscopy routinely (every 
day/week), performed the procedure. We continuously explained the procedure to the 
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patient, and asked for feedback between procedures. The positive and negative 
pressures used during the test procedures with the MI-E were increased gradually, 
providing the subject with the necessary time to get familiar with the in- and 
exsufflations; similar to the MI-E pressure titration they are used to in their daily 
clinical use of this device. If the patient expressed any signs of discomfort, the 
procedure was stopped, and higher pressures were not applied. The intervention with 
new MI-E settings was used in the same way as we would have done without this 
study; i.e. the use of MI-E was reduced and eventually stopped when treatment 
tolerance decreased clinically. The TFL was performed as gently as possible, and 
under careful observation. Ethical aspects were a continual focus.  
Before commencing on Studies #II and #III, we considered potential risks and 
discomfort to the participants to be minor when compared to the potential clinical 
gains for the individual participating patients, and the potential clinical gains for 
future ALS patients due to knowledge obtained from this study. In retrospect, it is our 
(humble) opinion that these reflections, made in advance, were in fact fulfilled. 
6.3 Discussion of the main findings of the study 
This study revealed inspiratory adduction of supraglottic structures during 
insufflation in patients with bulbar ALS, the opposite of the inspiratory abduction 
observed in non-bulbar patients and in healthy controls. This might explain treatment 
failures in bulbar ALS. The compromised size of the laryngeal inlet obstructs the 
inspiratory airflow from the MI-E, resulting in poor filling of the lungs during the 
first phase of cough. With disease progression, supraglottic inspiratory adduction 
appeared in spinal onset ALS patients before the evolvement of other bulbar signs 
and symptoms. Generally, the cough during MI-E altered with disease progression, 
and became slower, less expulsive and desynchronized. Individually customized 
settings seemed to promote more optimal laryngeal response patterns to MI-E. Our 
findings may benefit vulnerable patients through better handling of their daily 




6.3.1 Inspiratory closure 
Contradicting previous suggestions that upper airway collapse during exsufflation 
should explain MI-E inefficacy in ALS patients,141 our results suggest that the 
application of insufflation is the principle challenge, especially when bulbar 
dysfunction is present. Conceivably, the observed adduction prevents lung 
insufflation and leads to inadequate filling up of the lungs; a situation that will 
compromise attempts to assist the expiratory phase of cough through exsufflation, 
and thus lead to inefficient MI-E. However, the larynx is a highly complex organ that 
integrates a number of vital functions44-47 and similarly, ALS is a complex disease 
involving several mechanisms.6 Thus, inefficient MI-E in these patients is likely to be 
multifactorial and also vary between patients, and the relatively simple causal chain 
suggested above needs to be elaborated and substantiated by further and more 
comprehensive physiological study. Functional loss in ALS is often explained by the 
loss of motor control and strength,11,213 and more recently by laryngeal sensory 
insufficiency.87 Since ALS affects motor neurons in the brain and spinal cord, both 
afferent and efferent innervation may play a part in the adverse laryngeal response 
patterns during MI-E in these patients. In the following paragraphs, these aspects are 
discussed. 
Aerodynamics 
The aryepiglottic folds are relatively soft structures that are only provided with 
scattered muscle fibres. Therefore, adduction at the supraglottic level could, 
theoretically, be explained by the Bernoulli principle, i.e., increasing flows generating 
increasing negative pressures inside the laryngeal lumen, sucking the laryngeal 
structures inwards.70 This mechanism may conceivably be particularly important in 
progressive bulbar ALS characterised predominantly by hypotonic paresis.  
The Bernoulli principle may also play a role in epiglottic retroversion during 
insufflation. A retroflex floppy epiglottis has previously been described in ALS by  
Ito et al. in two patients during regular inspiration.187 The epiglottis has also been 
shown to be pressed into the laryngeal inlet by the positive pressures applied when 
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continuous positive airway pressure (CPAP) is used to treat patients with obstructive 
sleep apnoea214 and in patients with multiple system atrophy.72 Considerably higher 
pressures are applied when using MI-E than in these CPAP studies; i.e. pressures of 
20-50 cmH2O compared to 4-7 cmH2O, a factor that makes the Bernoulli principle 
even more relevant. 
Motor control and strength 
The size of the opening of the larynx is determined by a balance of forces between 
the abductor and adductor muscles. This balance can be influenced and disturbed by 
weakness of abductor muscles or increased activity of adductor muscles or vice versa. 
Essentially, the larynx has several small intrinsic adductors,54 but only one abductor 
muscle. Several vital laryngeal functions involve occlusion,58,59 and it has therefore 
been suggested that adductive movements by nature are dominant to abductive 
movements. This may be relevant for the findings of the present study; we found 
dominant adductive laryngeal movements in all patients with ALS compared to the 
healthy controls. Our results are supported by comparable findings from TFL 
examinations in other ALS patients. Polkey et al. reported two patients with bulbar 
dysfunction as having true vocal fold closure during both rapid spontaneous 
inspiration and expiration. Their interpretation was that this could be due to laryngeal 
abductor weakness, and suggested that when the weakness extends beyond a critical 
level, this may limit these patients ability to cough effectively.90 Van der Graaf et al. 
described true vocal fold dysfunction with abduction weakness, paresis or 
laryngospasm in four patients with different disease courses (both limb and bulbar 
onset). After needle myography examination, the authors suggested that this was a 
result of both over activity of the adductors, and signs of re-innervation in the 
abductors.188 Both these observations and our findings suggest that the motor deficit 
of intrinsic laryngeal muscles becomes weaker in ALS and that adductive movement 
becomes superior to the abduction. 
Sensory insufficiency  
Afferent activation in the larynx influences motor patterns.52 In ALS, applied MI-E 




extremely sensitive supraglottic receptors normally induces complex adductor 
reflexes that prevent foreign bodies from entering the airways.54 This reflex circuit 
may be hypo- or hyper-responsive or dysregulated in ALS patients,87 and therefore 
lead to inappropriate laryngeal closure, comparable to observations made in patients 
with Parkinson’s disease or brainstem compression.215,216 In fact, stimulation with 
positive air pressures has been used by otolaryngologists to provoke laryngeal reflex 
activities leading to both laryngeal closure and swallowing.52,217,218 Positive pressure 
to the mucosa in the laryngeal vestibule activates afferents in the internal branch of 
the superior laryngeal nerve, releasing the laryngeal closure reflex.217 Positive air 
pressure to the anterior facial area in the oral cavity activates glossopharyngeal 
afferents and elicit swallowing.218 Amin et al. used positive pressure sensory testing 
(up to 14 cmH2O) in combination with TFL to provoke swallowing in 22 ALS 
patients. More than half of these cases demonstrated abnormal laryngeal sensitivity.86 
The therapeutic use of positive pressures has previously been reported to provoke 
laryngeal narrowing. Jounieaux et al. revealed with laryngoscopic evaluation that 
positive pressure ventilation in healthy and awake subjects tended to result in 
progressive glottic narrowing, increasing the inspiratory resistance and thereby 
progressively reducing the fraction of air delivered to the lungs.219 This was further 
aggravated during stable sleep stage, and even more during a deep sleep stage.220 
Delguste et al. reported complete upper airway obstruction in association with NIV-
induced hypocapnia. The authors suggested that the use of positive pressure devices 
to extreme hyperventilation may increase the upper airway resistance and further 
proceed to a complete closure.221  
These studies support the view that therapeutic positive pressures applied by MI-E 
may provoke afferent responses that may lead to adverse laryngeal adduction that 
prevents airflow from entering the lungs. The observation made in the present study 
that positive pressures triggered swallowing, support the notion that laryngeal 
adduction during MI-E may be reflex mediated and linked to afferent activation. 
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Type of muscular paresis 
The type of muscle paresis may influence the laryngeal responses to MI-E. Motor 
innervation of the larynx is complex and only partially understood.60,61 In ALS, both 
upper and lower motor neuron failure is possible, as are spastic or hypotonic 
muscular responses. Differences in the two subtypes of bulbar ALS may influence 
laryngeal response patterns to MI-E.8-10  The observations made in Study #II 
indicated that in pseudobulbar ALS, laryngeal adduction occurs mainly at the glottic 
level. Due to small numbers of subjects, we were unable to separate predominant 
problems in hypotonic progressive bulbar palsy and hypertonic pseudobulbar 
patients. To our knowledge, these aspects are previously only examined in 
swallowing, but not during cough. Ertekin et al. examined swallowing in a 
heterogenic sample of 43 patients with ALS by electromyography. They found that 
the motor control of swallowing was disturbed, and indicated that hypo- or hyper 
reflexive states in the involved muscles could explain the findings. The analyses were 
unfortunately did not take into consideration bulbar symptoms or the type of bulbar 
symptoms, but focused on dysphagia.213 
ALS affects both corticobulbar and corticospinal pathways, both crucial for voluntary 
efforts.7 In patients with pseudobulbar paresis, patients are unable to perform forced 
manoeuvres (such as cough on command); however, reflex-induced cough may be 
preserved. Clinically, reduced coordination of laryngeal muscles will predispose the 
individual to the risk of choking and pulmonary aspiration.43,222 It seems reasonable 
to suggest that MI-E more easily triggers laryngeal adductor reflexes in a disease that 
is predominantly spastic. 
To conclude, MI-E can theoretically provoke a variety of responses at the laryngeal 
level in patients with ALS, which are capable of precluding non-invasive respiratory 
treatment efficacy. MI-E pressure application can lead to a disturbed balance between 
the forces that regulate the size of the laryngeal lumen, such as physical and 
aerodynamic forces relating to flow itself, muscle balances and reflex mechanisms. 
The present study was not set up to explain or disentangle these causal pathways. 




insufficiency or abnormality, and aerodynamics in the larynx. These issues are 
important to investigate in order to understand how we can expand on the therapeutic 
alternatives that are available to these vulnerable patients. 
6.3.2 Laryngeal responses in disease progression 
Laryngeal responses evolves 
As ALS progresses, also laryngeal responses evolve. Although longitudinal studies 
that include laryngeal examinations are lacking in ALS; laryngeal dysfunction has 
been suggested to occur both before and after the onset of other bulbar 
symptoms.45,188 Van der Graaf et al. suggested that ALS patients with adequate vital 
capacity are at risk of glottic narrowing, and that vocal cord dysfunction in ALS is 
not always related to major bulbar involvement.188  
The findings in the present longitudinal follow-up support this viewpoint. The larynx 
failed to respond adequately to externally applied positive pressures before this could 
be predicted by other signs generally used to signal bulbar involvement. Except from 
our Study #III, only one study has been published to date examining dysphagia with 
video fluoroscopy in ALS patients during disease progression. Higo et al. reported 
that parts of the swallowing movements slowed with disease progression. The authors 
suggested that this slowness of swallowing was mainly associated with tongue 
weakness.223 Also inappropriate true vocal fold motion has been a feature of the 
disease, observed by laryngoscopic examination even in spinal onset ALS - without 
other clinical bulbar signs. In that a cross-sectional study Tomik et al. found that the 
function of true vocal folds was abnormal in both bulbar and limb onset ALS.78 Both 
the studies of van der Graaf, Tomik et al. and Higo et al., in addition to the present 
Study #III, concur that laryngological examination may reveal early signs of vagus 
nerve involvement, and demonstrate “preclinical” bulbar failure in ALS. Thus, in 
respiratory management of ALS patients one should be aware that the larynx may 




Age of the patient may be a factor to consider when investigating the use of MI-E to 
assist cough. ALS patients are usually older than other neuromuscular patients who 
need to use a cough assist device. Age affects both strength and speed of the muscles 
that are involved in the cough process,224 and the lungs, thorax and glottis are affected 
by age related structural alterations.225 Expiratory strength is reduced, which affects 
the peak cough flow and relationship between two cough spikes.226,227 Also 
swallowing is influenced by the normal aging processes; swallowing slows with 
advancing age, which is a consequence of the initiation of the movements in the 
larynx and pharynx become slower.64,192 The sensitivity to trigger cough decreases 
and the risk of aspiration is increased in elderly people.225,228  
The implication of age on laryngeal responses to cough assist devices should be 
investigated further; e.g. by comparing the findings from the two control groups of 
the present study. 
Cough alters in ALS 
Study #III shows us that cough alters with disease progression in ALS, becoming less 
expulsive and less synchronized, more rigid and slower. Presumably, this is related to 
a gradual loss of adequate cough flow spikes and lower peak cough flows. Previous 
studies that have measured airflow have described this development. Chaudri et al. 
demonstrated that bulbar ALS patients were unable to generate cough airflow spikes, 
contributing to their ineffective cough.123 Polkey et al. also observed an inability to 
generate cough airflow spikes in patients with severe bulbar ALS and severe 
abdominal muscle weakness. The authors suggested that bulbar ALS patients are 
unable to achieve the necessary dynamic airway compression, and thus perform a 
huff instead of a cough. This may be related to muscular weakness and reduced 
glottic closure during cough maneuvers in ALS.90 It has been suggested that 
diaphragmatic muscular force is involved in generating the expulsive force of cough, 
and ALS disease progression will eventually affect also diaphragmatic regulation.43  
Inadequate dynamic airway compression, gradual loss of cough airflow spikes and 




eventually all contribute to development of ineffective cough in all patients with 
ALS. Given the heterogeneous nature of ALS, it seems fairly evident that this 
development must be complex and multifactorial, and that the causal chain is clearly 
insufficiently understood and also probably differs between patients. Therefore, 
cough clearance techniques must be individualized and tailored to the development of 
each and every patient, preferably based on objective information. In our view, the 
suggestions put forward in the present study - that laryngoscopy is performed during 
cough assist devices testing - seems reasonable. 
Swallowing during MI-E 
Reflex triggering of swallowing may further complicate altered cough in ALS, as it 
might lead to aspiration. In ALS, swallowing is altered: patients swallow lower 
volumes with prolonged apnoeic pauses. Swallowing may also be followed by an 
inspiration, increasing the risk of aspiration. This contrasts normal swallowing, where 
the epiglottis covers the laryngeal inlet with an apnoeic pause of 0.6-2.0 seconds, and 
is followed by expiration. As a result of the order in which muscles are affected, 
swallowing difficulties are one of the earliest complaints reported by patients 
manifesting bulbar ALS84 and swallowing is described to be most disturbed in 
pseudobulbar ALS.45 
Why MI-E triggers swallowing can be related to laryngeal afferent activation as 
discussed previously. In addition, both backward movement of the tongue base and 
retroflex movement of the epiglottis were frequent findings during insufflation and 
could potentially induce swallowing. In ALS, tongue muscle insufficiency is 
suggested to cause swallowing problems.85 In Study #III, retroflex movement of the 
epiglottis during insufflation could trigger swallowing and thus severely disturb 
timing and synchronizing of coughing. This can be related to the fact that the surface 
of the epiglottis is densely innervated by afferent fibres229 which might contribute to 
activation of afferent loops of reflex arcs as ALS progresses. Still, the retroflex 
movement of epiglottis was clearly not triggering swallowing in healthy subjects 
even it was frequently observed in several healthy controls both in Study #I and 
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Study #II; thus, these mechanisms may have a more important role in progressing 
ALS.  
To conclude, progressing ALS leads to disorganized laryngeal functions. Respiratory 
therapy in these patients therefore requires approaches that might differ from those 
applied in patients with other neuromuscular disorders without involvement of 
muscles with bulbar innervation. This study has indicated that when mechanical 
cough assist devices are used, great care must be taken to avoid applying pressures 
and cough cycles that the patients´ larynx is unable to handle, and that treatment 
needs to be individualized, preferably based on objective measures. Currently, in our 
opinion, direct laryngeal visualization during treatment is the best approach in 
challenging patients. This approach might be feasible also when titrating NIV for 
challenging ALS patients.222,230 
6.3.3 Individually customized MI-E therapy 
As dynamic collapse during exsufflation was previously thought to be the reason for 
ineffectiveness of MI-E in ALS, Kang and Bach suggested that ALS patients with 
bulbar dysfunction instead would benefit from a single deep insufflation combined 
with an abdominal thrust applied during the expulsive phase of cough.138,231 We 
included this intervention in our protocol. However, it seemed to be useless. Instead, 
and based on observations made in the present study, we developed a protocol for 
MI-E titration that should prevent inspiratory closure during insufflation. Figure 9 is 






Figure 9. A practical algorithm suggesting how to adjust the settings of MI-
E when used to treat ALS patients for airway secretion clearance problems. 
MI-E=Mechanical insufflation-exsufflation, ENT=Ear-Nose-Throat. 
Reproduced with permission from Thorax. Andersen et al.232 
Asymmetrical pressure settings 
We found that asymmetrical settings with lower insufflation pressures and flows 
appeared to be beneficial. To our knowledge, this is novel and has not been examined 
systematically in other studies including in ALS patients. Until recently, high 
symmetrical MI-E pressure settings have generally been considered to be most 
effective for neuromuscular patients,170,175 and most studies and clinicians apply 
settings of 40cmH2O or higher both for insufflation and for exsufflation.131,176,233 We 
showed in Study #I that this symmetrical approach could lead to hypopharyngeal 
constriction during exsufflation in healthy medical students, indicating that this 
phenomenon alone could not explain treatment failure with bulbar ALS. Results of 
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Study #II revealed that ALS patients with bulbar affection tended to close 
supraglottic structures during insufflation, and indicated that high positive pressures 
were the most provocative. The results of Study #III supported the findings that high 
pressures were most provoking to the larynx in ALS, inciting laryngeal closure 
already prior to other clinical bulbar symptoms. These observations suggest that a 
“disorganized larynx” in bulbar ALS patients prevent adequate filling of the lungs 
with insufflation, due to laryngeal closure. Applying negative pressures after an 
unsuccessful insufflation is bound to create only discomfort and a vacuum in the 
upper airways, leading to laryngeal collapse.  
Hence, we ended up exploring whether use of modified MI-E settings could succeed 
in keeping the laryngeal inlet open during insufflation for a prolonged period of time 
in patients with deteriorating ALS: we used lower insufflation than exsufflation 
pressures combined with more careful use of low insufflation flows. This approach is 
further supported by previous data published by Mustfa et al; they found that 
exsufflation alone could produce higher peak cough flow in bulbar ALS than 
insufflation alone; however, they did not examine other asymmetrical pressure 
settings.143 Senent et al. used a ventilator in patients with ALS to show that use of a 
positive pressure of 30 cmH2O prior to cough in fact produced higher peak cough 
flow than was achieved by using MI-E with ±40cmH2O.151 In Study #III we found 
further evidence suggesting that hypopharyngeal constriction occurred later in disease 
progression than laryngeal adduction during insufflation, thus supporting the theory 
that inability to fill the lungs with insufflation can create a vacuum-effect during 
subsequent exsufflation, and thereby aggravate hypopharyngeal narrowing. This 
emphasizes the importance of keeping the larynx open during insufflation to achieve 
a sufficient insufflation volume prior to cough. Increasing the insufflation time 
instead of the insufflation pressure is probably more feasible in achieving sufficient 
insufflation volumes; supported by a bench study by Gomez-Merino et al. who 
demonstrated that increasing the insufflation time is more important for optimal peak 
cough flow that increasing the exsufflation time.175 These complex relationships may 
explain the diverging results that are reported from studies of bulbar ALS patients, 




peak cough flow considered necessary for effective cough.126 In our opinion, too high 
insufflation pressures seem to be counterproductive as they might lead to laryngeal 
closure and thereby lower instead of increased insufflation volumes. 
MI-E cycle tailoring 
Rapid MI-E cycles may be challenging or impossible to handle for patients with ALS. 
It seems reasonable that successful MI-E requires that the larynx is "reset" after 
exsufflation and that possible swallowing or closure reflexes have been brought to an 
end before the next insufflation. An increased time interval between exsufflation and 
insufflation, or the use of only one cough cycle at a time, might thus be more 
appropriate to prepare the larynx for the next insufflation. These findings are highly 
explorative - for obvious reasons. However, they represent an attempt to address 
these matters with verifiable methods and outcomes, and should be the subject of 
future research. Given the changing and progressive nature of ALS with development 
of laryngeal responses being particularly difficult to predict, direct inspection of the 
larynx during ongoing treatment appears to be a simple and reasonable approach in 
patients with signs or symptoms suggesting treatment failure.   
6.4 Clinical implications  
The results of the present thesis potentially have direct clinical implications on how 
airway clearance therapy should be performed in patients with ALS. As alluded to by 
Simonds; patients with bulbar ALS may not have failed their MI-E therapy, but 
instead the previous therapy may in fact have failed the patients, due to erroneously 
applied settings.222 With the present studies we have achieved a better understanding 
of the laryngeal response patterns to MI-E in the various phenotypes of ALS, and we 
have been able to observe how these patterns evolve as the disease progresses. This 
study helped us - in our clinic - to establish better and individually tailored clinical 
respiratory treatment strategies for our participating patients, and we argue that our 
approach can successfully be applied also for patients with ALS in general. 
 90
Individually adjusted settings, carefully applied as patients deteriorate, may prevent 
adduction of laryngeal structures during insufflation, and thus prolong the period of 
successful non-invasive use of MI-E.  
A similar approach may also be appropriate when performing “start-up titration” of 
NIV settings; high inspiratory pressures may generate airway closure and therefore 
pressure should be gently titrated upwards.222 If problems are encountered, 
laryngoscopy can be a valuable tool in this process. This has already been preliminary 
reported by Farrero et al.; they adjusted ventilation parameters with the goal of 
achieving comfort for their patients in addition to adequate ventilation, and reported 
that over 50% of bulbar patients were successfully initiated on NIV. The authors 
attribute their success to a less “nihilistic attitude”, in-patient initiation, and overnight 
adaptation of settings.107 As alluded to before, therapeutic use of laryngoscopy may 
be a useful tool also during NIV titration, as suggested by the studies of Sayas 
Catalàn et al.207 and Georges et al.208 
In order to avoid bothersome, futile or even counterproductive handling of these 
vulnerable patients, we need proper and feasible methods that ensure optimal and 
extended use of non-invasive respiratory treatment. Various measures of lung 
function have also been suggested to this end.134,140,235 Additionally, various 
neurological scoring systems and clinical signs that indicate bulbar involvement are 
used as signals to execute caution. By observing medial collapse of laryngeal 
structures during insufflation before the appearance of these bulbar signs and 
symptoms, this thesis certainly questions their usefulness, and instead suggests direct 
assessment of the organ in question; i.e. the larynx of patients who are difficult to 
treat. Hence, TFL can be a valuable tool for a variety of respiratory therapeutic 
interventions in selected patients who do not respond as expected. 
There are no guidelines for the timing of tracheostomy, if that is a desired approach in 
a patient with ALS.106 The present study has provided data that may benefit ALS 
patients in that non-invasive treatment can be prolonged, potentially postponing the 




tracheostomy, and to optimize its timing, are exceedingly complex ethical and 
clinical issues that we did not set out to address in this thesis. 
6.5 Future prospects 
To examine functional outcomes of laryngeal adverse responses to MI-E by 
monitoring the airflow curve in parallel with TFL examination. 
To study if asymmetrical treatment pressures are effective in ALS. 
To develop and examine other outcome measures than peak cough flow for ALS 
patients that can be used to study the efficacy of MI-E or other cough augmentation 
techniques. 
To examine if therapeutic video recorded laryngoscopy can be beneficial in NIV 
titration in patients with ALS.  
To validate the findings of the present study in other and preferably larger patient 
populations. 




In this thesis we have shown that video-recorded flexible laryngoscopy is a feasible 
method to characterize laryngeal responses throughout an MI-E protocol applied to 
assist cough in healthy individuals, in the various phenotypes of ALS, and throughout 
typical ALS disease progression. Laryngeal movements during MI-E in healthy 
individuals were found to be mainly as described for normal cough. We have 
concluded that treatment failure with MI-E in ALS patients with bulbar symptoms is 
likely to be caused primarily by laryngeal adduction during insufflation, 
predominantly at the supraglottic level. This response precludes air-filling of the 
lungs during insufflation, causing discomfort and subsequent inefficient exsufflation. 
In disease progression, this occurred prior to the development of clinically evident 
signs of bulbar involvement. Cough patterns at the laryngeal level altered in ALS as 
the disease progressed, and became less synchronized with the MI-E. Reflex 
triggering of swallowing by positive air pressures applied by the MI-E could further 
complicate these matters and rapid MI-E cycles can be challenging or impossible to 
handle for patients with ALS. Individually tailored MI-E treatment can improve - and 
may possible extend - the use of non-invasive MI-E in ALS. TFL may prove an 
efficient tool assessing patients whose laryngeal responses to treatment are suspected 
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Kartlegging og oppfølging av strupens funksjon  




Bakgrunn og hensikt med denne studien 
 
Dette er et spørsmål til deg om å delta som frisk kontroll i en forskningsstudie som skal kartlegge 
hva som skjer i strupen hos pasienter med Amyotrofisk Lateral Sclerose (ALS) når de puster og 
hoster - og spesielt når de bruker en såkalt ”hostemaskin”. Vi tror at strupen kan være et viktig 
hinder for god hostefunksjon og derved et hinder for å få opp slim fra lungene hos disse 
pasientene. Dette er uheldig for pasienter med ALS og derfor viktig å undersøke nærmere.  
 
Tolkning av resultater fra undersøkelser av pasienter med ALS må baseres på sammenligning med 
tilsvarende undersøkelse av friske personer (kontroller). Derfor vil vi også kontakte friske voksne 
med spørsmål om å delta i et tilsvarende undersøkelsesprogram. Resultatene fra undersøkelsene 
av kontrollene vil bli sammenlignet med resultatene fra de som har diagnosen ALS. 
 
Ca 200-300 personer har ALS i Norge. Det er en sykdom som rammer hjernen og ryggmargen og som 
etterhvert leder til problemer bl.a. med å hoste og puste på grunn av svekkelse av muskulatur i bryst, 
tunge og hals. Behandling av ALS tar sikte på å opprettholde eller forbedre livskvaliteten lengst mulig.  
 
Hostemaskin er et hjelpemiddel til å få opp slim fra luftveiene. Den virker ved at luft først forsiktig 
blåses inn i lungene og deretter suges ut sammen med slim fra de sentrale luftveiene. Vi opplever at 
flere ALS pasienter får god hjelp av hostemaskinen, mens den fungerer dårligere hos andre. Vi tror at 
hindringen kan ligge i strupen, men dette har ikke blitt undersøkt tidligere. 
 
Målet med denne studien er å kartlegge strupens funksjon hos ALS pasienter over tid gjennom 
undersøkelser ved de regelmessige polikliniske kontrollene ved Haukeland Universitetssykehus 
(HUS). Bedre kunnskap på dette området kan bidra til bedre og mer individuelt tilpasset behandling 
hos pasienter med ALS. Dette vil kunne forbedre kvaliteten på behandlingen, også hos pasientene 
som deltar i denne aktuelle studien. Vi ønsker å lære av våre erfaringer slik at de kan bli til nytte også 
for andre pasienter. Derfor utføres undersøkelsene systematisk og innenfor rammene av en 
forskningsstudie. Forespørsel om deltagelse i denne studien er sendt til alle pasienter som er 
tilknyttet ALS klinikken på HUS.  
 
 
Deltagelsen av friske kontroller innebærer  
- Kartlegging av lungefunksjon. 
- Inspeksjon av strupen med laryngoskopi mens hostemaskin blir testet ut med forskjellige 
innstillinger. Laryngoskopi betyr inspeksjon av strupen ved hjelp av en myk slange med 
kamera som føres forsiktig inn gjennom nesen slik at man kan kikke ned på stemmebåndene. 
Undersøkelsen utføres rutinemessig mange ganger daglig ved sykehuset. Kamera gjør 
videoopptak av strupen som kan studeres etterpå. 
 




Mulige fordeler og ulemper 
Alle undersøkelser er trygge. Inspeksjon av strupen kan medføre ubehag ved neseskilleveggen og en 
følelse av kiling i halsen. For å redusere ubehaget vil neseslimhinnen behandles med vanlig nesespray 
som brukes ved forkjølelse, og deretter lokalbedøves ved hjelp av en gel (Xylocain®). Undersøkelsen 
utføres av en lege som utfører denne type undersøkelser av både barn og voksne med spørsmål om 
sykdommer i øvre luftveier.  
 
 
Hva skjer med informasjonen om deg?  
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med studien, 
dvs til å øke forståelsen vår for hva som skjer i strupen hos pasienter med ALS når de puster og 
hoster og bruker hostemaskin. Alle opplysningene og resultatene fra undersøkelsene vil i en 
forskningssammenheng bli behandlet uten navn og fødselsnummer eller andre direkte 
gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og resultater gjennom en 
navneliste. Det er kun personer knyttet til prosjektet som har adgang til denne navnelisten og som 
kan finne tilbake til deg. Alle som får innsyn i opplysninger har taushetsplikt. Det vil ikke være mulig å 




Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke 
til å delta i studien. Dersom du ønsker å delta, undertegner du samtykke erklæringen på siste side. 
Om du nå sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige 
behandling. Dersom du trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og 




Mer informasjon om studiet kan du få ved henvendelse til: 
Tiina Andersen  
Spesialfysioterapeut  
Nasjonalt Kompetansesenter for hjemmerespiratorbehandling, HUS 
Tlf.  55 97 84 86 / 80 
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Jeg er villig til å delta som frisk kontroll i studien  
 
Kartlegging og oppfølging av stemmebåndets bevegelse og stabilitet 
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Forespørsel om deltakelse i forskningsprosjektet 
 
Kartlegging og oppfølging av strupens funksjon  
hos personer med Amyotrofisk lateral sclerose (ALS) 
 
Bakgrunn og hensikt 
Dette er et spørsmål til deg om å delta i en forskningsstudie som skal kartlegge hva som skjer i 
strupen hos pasienter med Amyotrofisk Lateral Sclerose (ALS) når de puster og hoster - og spesielt 
når de bruker en såkalt ”hostemaskin”. Vi tror at strupen kan være et viktig hinder for god 
hostefunksjon og derved et hinder for å få opp slim fra lungene. Dette er uheldig for pasienter med 
ALS og derfor viktig å undersøke nærmere.  
 
Ca 200-300 personer har ALS i Norge. Det er en sykdom som rammer hjernen og ryggmargen og som 
etterhvert leder til bl.a. problemer med å hoste og puste på grunn av svekkelse av muskulatur i bryst, 
tunge og hals. Behandling av ALS tar sikte på å opprettholde eller forbedre livskvaliteten lengst mulig.  
Hostemaskin er et hjelpemiddel til å få opp slim fra luftveiene. Den virker ved at luft først forsiktig 
blåses inn i lungene og deretter suges ut sammen med slim fra de sentrale luftveiene. Vi opplever at 
flere ALS pasienter får god hjelp av hostemaskinen, mens den fungerer dårligere hos andre. Vi tror at 
hindringen kan ligge i strupen, men dette har ikke blitt undersøkt tidligere. 
 
Målet med denne studien er å kartlegge strupens funksjon over tid gjennom undersøkelser ved de 
regelmessige polikliniske kontrollene ved ALS klinikken, Haukeland Universitetssykehus (HUS). Bedre 
kunnskap på dette området kan bidra til bedre og mer individuelt tilpasset behandling hos pasienter 
med ALS. Dette vil kunne forbedre kvaliteten på behandlingen, også hos pasientene som deltar i 
denne aktuelle studien. Vi ønsker å lære av våre erfaringer slik at de kan bli til nytte også for andre 
pasienter. Derfor utføres undersøkelsene systematisk og innenfor rammene av en forskningsstudie. 
Forespørsel om deltagelse i denne studien er sendt til alle pasienter som er tilknyttet ALS klinikken på 
HUS. Deltagelse innebærer stort sett bare undersøkelser som normalt uansett utføres ved ALS. 
 
Tolkning av resultater fra undersøkelser av pasienter med ALS må baseres på sammenligning med 
tilsvarende undersøkelse av friske personer (kontroller). Derfor vil vi også kontakte friske voksne med 
spørsmål om å delta i et tilsvarende undersøkelsesprogram. Resultatene fra undersøkelsene av 
kontrollene vil bli sammenlignet med resultatene fra de som har diagnosen ALS. 
 
Deltagelsen innebærer  
Første kartlegging: 
- Undersøkelse av en lege (spesialist i neurologi). 
- Kartlegging av lungefunksjon. 
- Inspeksjon av strupen med laryngoskopi mens man blir bedt om å gjøre enkle oppgaver som 
gir kunnskap om strupens funksjon. Hostemaskin blir testet ut med forskjellige innstillinger. 
Laryngoskopi betyr inspeksjon av strupen ved hjelp av en myk slange med kamera som føres 
forsiktig inn gjennom nesen slik at man kan kikke ned på stemmebåndene. Undersøkelsen 
utføres rutinemessig mange ganger daglig ved sykehuset. Kamera gjør videoopptak av 
strupen som kan studeres etterpå. 
- Spørreskjema om hoste og pustefunksjon og forhold knyttet til ALS og livskvalitet 
Oppfølging: 
- Kort inspeksjon av strupen mens man blir bedt om å gjøre enkle oppgaver tilsvarende den 
første undersøkelsen.  
- Oppfølging av funksjon i svelget, lungefunksjonen og sykdomsutviklingen. 
- Oppfølgende spørsmål fra spørreskjema om hoste og pustefunksjon og forhold knyttet til ALS 
og livskvalitet 
 
Inspeksjon av strupen første gang utføres poliklinisk på en time avtalt sammen med deg. De andre 
undersøkelser utføres når du har vanlige kontrolltimer ved ALS poliklinikken.  
 
 
Mulige fordeler og ulemper 
Alle undersøkelser er trygge. Du vil få en grundig vurdering av hvorvidt hostemaskinen er et aktuelt 
hjelpemiddel for deg. Inspeksjon av strupen kan medføre ubehag ved neseskilleveggen og en følelse 
av kiling i halsen. For å redusere ubehaget vil neseslimhinnen behandles med vanlig nesespray som 
brukes ved forkjølelse, og deretter lokalbedøves ved hjelp av en gel (Xylocain®). Undersøkelsen 
utføres av en erfaren øre-nese-hals lege som utfører denne type undersøkelser daglig av både barn 
og voksne med spørsmål om sykdommer i øvre luftveier.  
 
Hva skjer med informasjonen om deg?  
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med studien, 
dvs til å øke forståelsen vår for hva som skjer i strupen hos pasienter med ALS når de puster og 
hoster og bruker hostemaskin. Alle opplysningene og resultatene fra undersøkelsene vil i en 
forskningssammenheng bli behandlet uten navn og fødselsnummer eller andre direkte 
gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og resultater gjennom en 
navneliste. Det er kun personer knyttet til prosjektet som har adgang til denne navnelisten og som 
kan finne tilbake til deg. Alle som får innsyn i opplysninger har taushetsplikt. Det vil ikke være mulig å 
identifisere deg i resultatene fra studien når disse publiseres.  
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. Dersom du 
ønsker å delta, undertegner du samtykke erklæringen på siste side. Om du nå sier ja til å delta, kan 
du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du trekker 
deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre 
opplysningene allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
 
Mer informasjon om studiet kan du få ved henvendelse til: 
Tiina Andersen  
Spesialfysioterapeut  
Nasjonalt Kompetansesenter for hjemmerespiratorbehandling, HUS 
Tlf.  55 97 84 86 / 80 






Det planlagte prosjektet er et samarbeidsprosjekt mellom 1Nasjonalt kompetansesenter for 
hjemmerespiratorbehandling, 2Lungeavdelingen, 3Neurologisk avdelingen, 4Øre Nese Hals avdeling, 
5Fysioterapiavdeling og 6Barneklinikken på Haukeland Universitetssykehus, 7Universitet i Bergen samt 
8Høgskolen i Bergen.  
 
 
Ole-Bjørn Tysnes   John-Helge Heimdal   Thomas Halvorsen 
Overlege, prof. dr med. 
3, 7
  Overlege, dr.med. 
4
   Overlege, dr.med. 
6 





Tiina Andersen    Ove Fondenes     Ola Drange Røksund  
Spesialfysioterapeut 
1, 2, 5, 8
  Overlege, senterleder 
1, 2












Jeg tillater innsyn i min journal i den grad dette er viktig for å få fram 
opplysninger som er relevant for denne studien  
 





Jeg er villig til å delta i studien  
 
Kartlegging og oppfølging av stemmebåndets bevegelse og stabilitet 











Sted og dato___________________________________________________ 
 
_____________________________________________________________ 







Stedfortredende samtykke når berettiget, enten i tillegg til personen selv eller istedenfor 
 
Sted og dato___________________________________________________ 
 
_____________________________________________________________ 
Signert av nærstående 

 116





Laryngeal response patterns influence the efficacy
of mechanical assisted cough in amyotrophic lateral
sclerosis
Tiina Andersen,1,2,3 Astrid Sandnes,3 Anne Kristine Brekka,4 Magnus Hilland,5
Hege Clemm,3,6 Ove Fondenes,1 Ole-Bjørn Tysnes,7,8 John-Helge Heimdal,5,8
Thomas Halvorsen,3,6 Maria Vollsæter,1,3,6 Ola Drange Røksund4,6
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
thoraxjnl-2015-207555).





of Excellence for Home
Mechanical Ventilation,
Haukeland University Hospital,
Bergen 5021, Norway; tiina.
andersen@helse-bergen.no
Received 17 July 2015
Revised 22 March 2016





To cite: Andersen T,
Sandnes A, Brekka AK,
et al. Thorax 2017;72:221–
229.
ABSTRACT
Background Most patients with amyotrophic lateral
sclerosis (ALS) are treated with mechanical insufflation–
exsufflation (MI-E) in order to improve cough. This
method often fails in ALS with bulbar involvement,
allegedly due to upper-airway malfunction. We have
studied this phenomenon in detail with laryngoscopy to
unravel information that could lead to better treatment.
Methods We conducted a cross-sectional study of 20
patients with ALS and 20 healthy age-matched and sex-
matched volunteers. We used video-recorded flexible
transnasal fibre-optic laryngoscopy during MI-E
undertaken according to a standardised protocol,
applying pressures of ±20 to ±50 cm H2O. Laryngeal
movements were assessed from video files. ALS type and
characteristics of upper and lower motor neuron
symptoms were determined.
Results At the supraglottic level, all patients with ALS
and bulbar symptoms (n=14) adducted their laryngeal
structures during insufflation. At the glottic level, initial
abduction followed by subsequent adduction was observed
in all patients with ALS during insufflation and exsufflation.
Hypopharyngeal constriction during exsufflation was
observed in all subjects, most prominently in patients with
ALS and bulbar symptoms. Healthy subjects and patients
with ALS and no bulbar symptoms (n=6) coordinated their
cough well during MI-E.
Conclusions Laryngoscopy during ongoing MI-E in
patients with ALS and bulbar symptoms revealed laryngeal
adduction especially during insufflation but also during
exsufflation, thereby severely compromising the size of the
laryngeal inlet in some patients. Individually customised
settings can prevent this and thereby improve and extend
the use of non-invasive MI-E.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an incurable
and highly disabling neurodegenerative disease of
upper and lower motor neurons. Treatment is
largely symptomatic, and average life expectancy at
the time of the diagnosis is 2–3 years unless ventila-
tory assistance is provided.1
ALS is classified as ‘spinal’ if symptom onset
affects the limbs predominantly, and as ‘bulbar’ if
the disease presents with difficulty in speaking,
swallowing or coughing. Paresis to predominantly
upper motor neurons leads primarily to spasticity,
whereas paresis of lower motor neurons leads to
flaccidity.2 Regardless of the subtype, ALS pro-
gresses and eventually encompasses all skeletal
muscles.3 Involvement of respiratory muscles limits
respiratory function and cough, thereby leading to
secretion accumulation, lung infections and, even-
tually, respiratory failure.3–6 Effective augmentation
of cough is vital for clearance of airway secretions
in these patients and fundamental for the preven-
tion and treatment of pneumonias.6 7
In a voluntary cough, inspiratory muscles increase
the lung volume, laryngeal muscles coordinate
opening and closure of the glottis and expiratory
muscles increase the thoracoabdominal pressure.8
These interactions are disturbed in neuromuscular
disorders.7 9 Mechanical insufflation-exsufflation
(MI-E) is used widely to assist cough mechanically
by applying positive and negative pressure changes
to the airways, either non-invasively via a mask or
invasively via a tracheostomy.10 11 It has been
hypothesised that coordinated glottic movements are
required for MI-E to be effective.12 Non-invasive
MI-E can be difficult to apply in patients with the
Key messages
What is the key question?
▸ Mechanical insufflation–exsufflation (MI-E) is
an efficient tool used to improve cough in most
patients with neuromuscular disorders, but the
method often fails when bulbar involvement is
present.
What is the bottom line?
▸ We used laryngoscopy during ongoing MI-E
and saw that patients with bulbar amyotrophic
lateral sclerosis (ALS) were prone to adduct
laryngeal structures throughout the various
pressure cycles, thereby severely obstructing the
airflow and the effect of the treatment.
Why read on?
▸ In patients with bulbar ALS, cough assistance
with MI-E should be delivered carefully and
according to the criteria suggested in the
present study.
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bulbar subtype of ALS. This problem may be due to dysfunction
of bulbar-innervated muscles, but the basic mechanisms are not
understood.
The laryngeal response to MI-E in patients with ALS has
never been studied. Here, we investigated the laryngeal response
patterns to MI-E in ALS to improve the treatment that we can
offer to these severely ill patients.
METHODS
Neurological assessment and definitions
ALS was diagnosed by a senior neurologist (O-BT) in accord-
ance with the revised criteria set by the El Escorial World
Federation of Neurology.13 14 The disease was classified as
‘spinal ALS’, ‘ALS with progressive bulbar palsy’ (hypotonic
bulbar onset with dysarthria, tongue atrophy and absence of jaw
reflex) or ‘ALS with pseudobulbar palsy’ (spastic bulbar onset
with dysarthria, exaggerated jaw reflex and no tongue atrophy).
Patients were assessed using the ALS Functional Rating Scale-
revised (ALSFRS-r).15 Bulbar impairment score (BIS) was evalu-
ated from the ALSFRS-r, from where the items of speech and
swallowing were calculated.16 Dysphagia was determined using
the 100 mL water swallow test.17 18
Subjects
This was a cross-sectional observational population-based study
of 20 patients with ALS who had not undergone tracheostomy
and 20 neurologically healthy age-matched and sex-matched
controls. Exclusion criteria were age <18 years, history of laryn-
gospasm, sensitisation to Xylocain (anaesthetic used during
laryngoscopy), pneumothorax, additional lung disease, cancer,
acute infection of the chest 1 month before study commence-
ment and mental instability.
Approximately 20 patients with ALS who have not undergone
tracheostomy are usually enrolled at all times at the ALS clinic
at Haukeland University Hospital (Bergen, Norway), which
serves a population of ≈500 000 inhabitants. At the start of this
study, 17 patients were enrolled at the clinic and 20 new
patients were diagnosed and enrolled during the 1.5-year
recruitment period from December 2011 to June 2013. All 37
patients were informed about the study and invited to partici-
pate. Thirteen patients declined and four died soon after being
invited, leaving 20 participants. Reasons for non-participation
were severe disease/fatigue (n=7), or limb-onset ALS without
bulbar symptoms and, therefore, no interest in participation
(n=6). The study protocol was approved by the Regional
Committee for Medical Research Ethics. Written informed
consent was obtained from all participants.
Pulmonary function and respiratory strength
Spirometry was undertaken with a Vmax 22 Encore system
(SensorMedics, Yorba Linda, California, USA). FVC, FEV1 and
peak expiratory flow were measured seated, with a nose clip.
Slow vital capacity was measured with a Respirometer (nSpire
Health, Hertford, UK). Peak cough flow was measured using a
hand-held Peak Flow Meter (Vitalograph, Ennis, Ireland).
Plateau values (average of 1 s) of the maximal inspiratory (Pimax)
and expiratory (Pemax) muscle strength and sniff nasal inspira-
tory pressure (SNIP) were measured seated using a Respiratory
Pressure Meter (Micro RPM; Micro Medical, Rochester, UK).
SNIP was measured at functional residual capacity, Pimax at
residual volume and Pemax at total lung capacity. The highest
value from three or more attempts was selected for analyses and
standardised to predicted percentages.19–22
Video-recorded transnasal fibre-optic laryngoscopy during
MI-E
Video-recorded transnasal fibre-optic laryngoscopy (ENF-P3;
Olympus, Tokyo, Japan) was used to visualise laryngeal anatomy
at baseline and response patterns during MI-E (Cough Assist;
Respironics, Murrysville, Pennsylvania, USA). We used a set-up
described in detail previously, except that the laryngoscope was
supported manually (see online supplementary figure S1)
instead of using a customised headgear.23 A standardised MI-E
protocol was used.23 The protocol comprised 12 intervention
arms with various combinations of pressures, instructions and
manual thoracic thrust (see online supplementary table S2).
Pressures of ±20, ±30, ±40 and ±50 cm H2O were used
with specific instructions. For MI-E in automated mode with 2 s
insufflation, 2 s exsufflation and 1 s pause, the instructions were
to ‘inhale’ actively when insufflation was started and to (A)
‘exhale’ or (B) ‘cough’ actively when the device switched to
exsufflation. For MI in manual mode with 2 s insufflation fol-
lowed by manually assisted thoracic thrust, the instructions were
to ‘inhale’ actively when insufflation was started and to ‘cough’
actively during the thoracic thrust.
In case of patient discomfort, the procedure was stopped and
higher examination pressures were not applied.
Analyses of observations
Altogether, 480 recordings were scheduled for assessment, that
is, one recording from 12 intervention arms in 20 patients and
20 control subjects. With respect to assessment of observations,
MI-E cycles were edited into three phases of interest: (i) insuf-
flation, (ii) pressure drop (from positive to negative) and (iii)
active exsufflation or the voluntary cough with no negative pres-
sure applied. The onset and offset of each phase were observed
and defined from the parallel video recording of the MI-E man-
ometer.23 Video recordings were assessed systematically, as
described previously,23 by two trained raters (TA and AKB).
Main features were described at glottic, supraglottic and hypo-
pharyngeal levels (see online supplementary figure S3).
Laryngeal anatomy and motion at rest were evaluated by a
senior laryngologist ( J-HH).
Statistical analyses
The χ2 test, or Fisher’s exact test if expected cell counts were
less than five, were applied to assess differences between groups
with regard to categorical data. Background data were given as
group means with SDs. The number of subjects with the
described patterns of laryngeal movements during MI-E was
given as group counts and percentages. Statistical analyses were
conducted using SPSS V.21.0 (IBM, Armonk, USA). The two-
sided significance level was set at 0.05.
RESULTS
Patient characteristics
Of 20 participating patients with ALS, six had limb onset with
no bulbar symptoms and 14 had bulbar symptoms (table 1); of
these, seven had pseudobulbar (spastic) ALS and seven had pro-
gressive bulbar (hypotonic) ALS. Lung-function characteristics in
ALS were lower than predicted (table 1). In patients with pro-
gressive bulbar ALS, 4/7 subjects had an abnormal epiglottis:
three had a juvenile and high-standing epiglottis, and in one
patient the epiglottis was considered ‘floppy’. Retention of
secretions/sputum was observed in 4/7 patients with progressive
bulbar ALS, in 2/7 cases with pseudobulbar ALS, in 2/6 subjects
with non-bulbar ALS and in 1/20 healthy controls.
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Laryngeal response to MI-E
In total, 453 (94%) of 480 scheduled recordings were analysed.
Four patients with bulbar symptoms completed only parts of
the MI-E protocol due to discomfort from the applied pres-
sures, that is, one patient (progressive bulbar ALS) interrupted
the protocol after pressures of ±20 cm H2O (missing 9/12 inter-
vention arms), one patient (pseudobulbar ALS) after
±30 cm H2O (missing 6/12 intervention arms) and two patients
(one pseudobulbar and one progressive bulbar ALS) after
±40 cm H2O (both patients missing 3/12 intervention arms).
Technical failures led to loss of video recordings in one healthy
control at examining pressures of ±40 and ±50 cm H2O
(missing 6/12 intervention arms).
In general, the larynx moved downwards during applied insuf-
flation and upwards (cranially) during exsufflation. (See table 2
for overall descriptions and online supplementary video 1 for the
laryngeal response in a patient with non-bulbar ALS; online
supplementary video 2 in a healthy control; online supplemen-
tary video 3 in a patient with progressive bulbar ALS; online
supplementary video 4 in a patient with pseudobulbar ALS.)
Adequate laryngeal control was defined as described for normal
cough in the literature,8 and presented as initial abduction of the
true vocal folds (TVF) and aryepiglottic folds (AEF), and there-
after glottic closure with subsequent rapid opening when cough-
ing, abduction of the TVF and AEF followed by sequential
closures and/or narrowing in the exhalation phase of the cough.
Response at the glottic level
Observations at the glottic level were not possible in some patients
with ALS and bulbar symptoms, because adduction of AEF and/or
the hypopharyngeal area obscured the view of TVF, particularly in
the high-pressure ranges of 40–50 cm H2O. Observations at the
glottic level were based on successful visualisation of MI-E cycles
(TVF responses A, B, G, I, M, S, N1, N2 and N3 in figure 1 and
online supplementary tables S4, S5 and S6).
There were significant differences between patients with ALS
and healthy controls with respect to TVF adduction subsequent
to the initial abduction during insufflation (response B in figure 1
and in online supplementary table S4) and exsufflation. Varying
the instructions (to cough or exhale during negative pressures or
to cough without applied negative pressure) did not influence the
groups differently (response N1, N2 and N3 in figure 1 and
online supplementary table S6).
Response at the supraglottic level
AEF responses are presented as C, D, H, J, O and P (figure 2
and online supplementary tables S4, S5 and S6). Medial rotation
of the cuneiform tubercles accompanied by considerable adduc-
tion of the AEF was observed during insufflation (initially or
subsequent to abduction) in all patients with bulbar ALS (online
supplementary table S4 and response C and D in figure 2).
A retroflex movement of epiglottis (a passive dorsal rotation)
was observed to partly occlude the laryngeal inlet in some cases,
either as a rapid movement or lasting throughout the insuffla-
tion (responses E, K and Q (figure 2 and online supplementary
tables S4, S5 and S6)).
Oesophageal opening was observed during insufflation in two
patients with progressive bulbar ALS. Both subjects were
observed to burp afterwards, suggesting that (part of) the insuf-
flation volume ended up in the oesophagus and stomach instead
of the lungs.
Response at the tongue base and at the hypopharyngeal
level
There were significant differences between healthy controls and
patients with ALS with regard to backward movement of the
tongue base during insufflation and during the pressure drop
(responses F and L in figure 3 and online supplementary tables
S4 and S5).
Constriction of the hypopharynx during exsufflation was
observed in healthy controls and in patients with ALS, regard-
less of the presence of bulbar symptoms. In patients with ALS
and bulbar symptoms, hypopharyngeal constriction was more
prominent in those with progressive bulbar paresis. The
Table 1 Background characteristics of the study participants (n=40)





Male/female ratio 13/7 13/7 6/0 7/7
Age, years 66.9 (7.2) 68.7 (9.3) 65.8 (9.2) 69.9 (9.4)
BMI, kg/m2 23.9 (2.4) 23.6 (4.3) 23.5 (1.8) 23.6 (5.1)
FVC, % pred 113.6 (16.0) 67.4 (22.1) 73.5 (18.8) 64.5 (23.7)
FEV1, % pred 107.4 (19.0) 70.6 (25.7) 76.0 (22.0) 68.1 (27.7)
SVC, L 4.15 (1.3) 2.92 (1.0) 3.6 (0.7) 2.6 (1.0)
SVC, % pred 110.6 (20.1) 76.1 (22.5) 78.7 (12.9) 75.0 (26.2)
PCF, L/min 484.5 (130.2) 266.8 (145.8) 340.8 (198.6) 232.6 (108.4)
Pimax, cm H2O 95.2 (23.6) 43.3 (20.9) 54.2 (18.9) 38.6 (20.5)
Pimax, % pred 111.3 (24.9) 52.9 (23.7) 58.3 (20.6) 50.6 (25.2)
Pemax, cm H2O 140.8 (37.9) 50.4 (30.0) 80.2 (32.1) 37.6 (18.3)
Pemax, % pred 140.1 (34.3) 49.4 (24.8) 68.2 (30.3) 41.3 (17.6)
SNIP, cm H2O 91.2 (33.7) 38.6 (17.9) 47.7 (22.2) 33.6 (13.8)
SNIP, % pred 99.1 (34.6) 42.6 (19.0) 48.1 (22.9) 39.7 (16.9)
WST, mL/s 31.50 (7.7) 12.3 (11.4) 25.8 (7.6) 5.5 (4.9)
ALSFRS-r – 36.7 (8.4) 39.0 (7.5) 35.6 (8.9)
BIS – 6.0 (2.3) 8.0 (0) 5.0 (2.3)
Figures are group means with SDs.
ALS, amyotrophic lateral sclerosis; ALS Functional Rating Scale-revised; BIS, bulbar impairment scale; BMI, body mass index; PCF, peak cough flow; Pemax, maximal expiratory mouth
pressure; Pimax, maximal inspiratory mouth pressure; SNIP, sniff nasal inspiratory pressure; SVC, slow vital capacity; WST, water swallow test.
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hypopharynx was totally constricted in 4/7 patients with pro-
gressive bulbar paresis and in 1/7 patients with pseudobulbar
paresis (responses R1, R2 and R3 in figure 3 and online
supplementary table S6).
Differences in laryngeal movements between patients with
pseudobulbar and progressive bulbar ALS were not significant.
A few significant values were observed between observations of
healthy controls and patients with ALS and bulbar symptoms,
and between patients with ALS with and without bulbar
symptoms. Due to a multiple-testing problem, these results
should be interpreted with caution. However, we saw a pattern
in comparison between controls and patients with ALS and
bulbar symptoms with regard to backward movement of the
tongue base during the pressure drop and in subsequent adduc-
tion of TVF during exsufflation (see online supplementary
tables S4–S6).
DISCUSSION
This is the first study to show that video-recorded flexible laryn-
goscopy is a feasible method to characterise laryngeal responses
throughout MI-E in patients with ALS. Results clearly indicated
that MI-E in patients with bulbar symptoms was associated with
adduction of supraglottic laryngeal structures during insuffla-
tion, and that this seemed to compromise airflow. Backward
movement of the tongue base during insufflation, potentially
obstructing airflow at the hypopharynx, was more prominent in
patients with ALS than in healthy controls. Moreover, patients
with ALS, irrespective of subtype, were more likely to adduct
the vocal folds during insufflation and exsufflation. Patients with
ALS, without bulbar symptoms, could cough in a coordinated
way, similar to that seen in healthy controls.
The main strength of this study was provision of important
knowledge on a challenging clinical problem achieved using
objective and verifiable methods in a population-based sample
of patients whose data were compared with those of healthy
matched volunteers. The small study cohort was a limitation,
complicating statistical handling and rendering the study at risk
of particularly type-II errors (ie, failure to detect significant dif-
ferences that may have been present). A priori power calculation
could not be undertaken, because the data distribution was not
known when planning the study.24
Transnasal fibre-optic laryngoscopy during ongoing MI-E in
patients with ALS has not been described previously, but has
been used to describe the larynx during simple tasks (eg, vocalis-
ing, spontaneous cough and forced exhalation).25 26 We
encountered some technical challenges. First, as the larynx
moved downwards and upwards during insufflation and exsuf-
flation, dynamic adjustments of the laryngoscope position were
required. Sometimes, airway secretions led to poor-quality video
recordings, and pretreatment aiming to clear secretions could
have been considered. Adduction of supraglottic structures pre-
cluded visual access to the vocal folds in some patients.
The present study suggests that adduction of primarily supra-
glottic laryngeal structures during insufflation may be a critical
issue when carrying out MI-E in patients with ALS and bulbar
symptoms. Conceivably, the observed adduction prevents lung
insufflation before exsufflation, thereby compromising the effect
of MI-E. We cannot explain these response patterns, but can only
speculate. There is only one abductor muscle in the larynx, the
posterior cricoarytenoid muscle, but several small intrinsic
adductors.27 Intrinsic laryngeal muscles interact in a complex
way during cough, speech and swallowing, but always act in
concert. Stimulation of extremely sensitive receptors in the supra-
glottic larynx usually induces complex adductor reflexes that, for
example, prevent foreign bodies from entering the airways.27
This reflex circuit may be hyper-responsive or dysregulated in
patients with ALS and, therefore, lead to inappropriate laryngeal
closure, comparable with the observations made in patients with
Parkinson’s disease or brainstem compression.28 29 Tomik et al25
observed early dysfunction of the vagal nerve before any clinical
signs of bulbar dysfunction in patients with spinal ALS. The
observed vocal fold adduction in our study supports this finding.
Differences in the two subtypes of bulbar ALS may influence
laryngeal response patterns to MI-E, that is, progressive (hypo-
tonic) versus pseudobulbar (spastic) ALS. In pseudobulbar ALS,
laryngeal adduction occurred mainly at the glottic level at rela-
tively high insufflation pressures. It seems reasonable to suggest
that positive pressures more easily trigger laryngeal adductor
reflexes in a disease that is predominantly spastic. AEF are rela-
tively soft structures provided with only scattered muscle fibres.
Therefore, adduction at the supraglottic level could, theoretically,
be explained by the Bernoulli principle: increasing airflow initiates
negative intraluminal pressures that eventually cause medial col-
lapse.30 This mechanism may conceivably be particularly import-
ant in progressive bulbar ALS characterised predominantly by
hypotonic paresis. An abnormal high-standing epiglottis may have
a practical implication by compromising the laryngeal inlet during
insufflation due to retroflex movements caused by the positive
pressures, as demonstrated also during treatment with CPAP in
patients with obstructive sleep apnoea.31
Table 2 Description of laryngeal response patterns during the MI-E protocol (n=40)
Glottic level Supraglottic level Tongue base and hypopharyngeal level
Subjects (N=20) True vocal folds (TVF) Aryepiglottic folds (AEF) Epiglottis (EG)
Base of the
tongue (BT) Hypopharynx (HP)




















Backward in 5/7 Constriction in all, and
very narrow in 4/7
Pseudobulbar ALS
(n=7)
Inadequate control§ in insufflation;
in 3/7and in 1/7 in exsufflation
Adduction in insufflation in all
(but in 4/7, only at higher





Constriction in all, and
very narrow in 1/7
*Normal cough, that is, TVF abduction in insufflation, glottic closure when coughing and TVF abduction+sequential closures and/or narrowing in exsufflation.
†AEF follows the movements of the TVF.
§Very small TVF opening in insufflation or in exsufflation.
ALS, amyotrophic lateral sclerosis; MIE, mechanical insufflation–exsufflation.
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Hypopharyngeal constriction during exsufflation was
observed to varying extents in all study subjects, as well as
healthy controls. This finding confirms reports of upper-airway
narrowing at pharyngeal and oropharyngeal levels upon appli-
cation of negative pressures during exhalation in healthy sub-
jects.32–34 This phenomenon has been used to explain the
Figure 1 Laryngeal response at the glottic level. Figures are percentages of the sample with the described response. *Significant difference
between healthy volunteers and patients with ALS. ALS, amyotrophic lateral sclerosis; TVF, true vocal folds.
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ineffectiveness of MI-E in patients with ALS.35 Sancho et al
undertook CT during MI-E at baseline and during exsufflation
in three patients with ALS. They reported varying reductions
of the lateral diameter at the level of nasopharynx, uvula and
pharynx during the exsufflation phase at −40 cm H2O.12 The
response during insufflation was not examined. They suggested
Figure 2 Laryngeal response at the supraglottic level. Figures are percentages of the sample with the described response.*Significant difference
between healthy volunteers and patients with ALS. AEF, aryepiglottic folds; ALS, amyotrophic lateral sclerosis.
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that MI-E should be carried out by applying a single insuffla-
tion followed by a manually assisted cough instead of active
exsufflation with negative pressures.35 36 Hypopharyngeal con-
striction during exsufflation was observed in healthy controls
and patients with ALS in the present study; so, this phenom-
enon alone cannot explain treatment failure in bulbar ALS.
Moreover, inability to fill the lungs during insufflation because
of the observed supraglottic adduction would create a vacuum
during the subsequent active exsufflation, and thereby aggravate
hypopharyngeal constriction. If this hypothesis is correct, a
single insufflation followed by a manually assisted cough
cannot help patients with bulbar ALS to cough more effect-
ively, but will be both uncomfortable and unproductive.
The present study suggests that an individual approach to
MI-E used in respiratory airway therapy is highly important.
Lower positive pressures and airflow combined with longer
inspiratory times may contribute to better laryngeal stability
during insufflation, perhaps by preventing or reducing the impact
of protective laryngeal reflex circuits and the intraluminal suction
forces induced by the Bernoulli effect (figure 4). Patients with
bulbar insufficiency may, therefore, be more likely to obtain suffi-
cient inspiratory volumes, a situation that would improve the
conditions for exsufflation of the lungs. The phasic relationship
that exists between the posterior cricoarytenoid muscle and dia-
phragm is a feature that could, theoretically, be exploited clinic-
ally. That is, when the diaphragm contracts, the activity of the
posterior cricoarytenoid muscle increases in a coordinated
manner due to vagal stimulation, thereby abducting the larynx.27
If the patient is instructed to inhale actively before active insuffla-
tion with MI-E, this act would, theoretically, lead to better laryn-
geal abduction and facilitate airflow. Recently, MI-E devices with
a ‘trigger’ function linked to insufflation have become available,
and these mechanisms should be studied closely.
A better understanding of laryngeal dysfunction as ALS pro-
gresses in its various phenotypes can help establish better (and
hopefully individually tailored) clinical respiratory treatment
strategies for these patients, and perhaps also for other patients
with bulbar-innervated muscle dysfunction.
CONCLUSION
Video-recorded flexible laryngoscopy is a feasible method to
characterise laryngeal responses throughout an MI-E protocol in
patients with ALS. Treatment failure with MI-E in patients with
bulbar symptoms is likely to be caused primarily by laryngeal
adduction during insufflation, predominantly at the supraglottic
level. This response precludes air-filling of the lungs during
Figure 3 Laryngeal response at the tongue base and hypopharyngeal level. Figures are percentages of the sample with the described response.
*Significant difference between healthy volunteers and patients with amyotrophic lateral sclerosis (ALS).
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insufflation, causing discomfort and subsequent inefficient
exsufflation. We propose that individually customised settings
for pressure and flow can improve and extend the use of non-
invasive MI-E in ALS, and that flexible laryngoscopy can be an
efficient tool in this respect in selected patients who do not
respond as expected.
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SUPPLEMENTARY FIGURES 
Figure S1. The setup with a laryngoscope passing through a modified interface with the 
laryngoscope supported and adjusted manually. Situation arranged. 
 
Figure S2. Examination was recorded with two continuous videos on the same screen, and 
showed the laryngeal view and phases on the MI-E device synchronously. Anatomic 
landmarks are illustrated on the laryngeal top view. 
 
 
LEGENDS FOR SUPPLEMENTARY VIDEO FILES  
Supplementary Video 1. Laryngeal response to mechanical insufflation–exsufflation (MI-E) 
in a patient with non-bulbar ALS visualised in real-time and slow motion by video-recorded 
transnasal fibreoptic laryngoscopy.  
Supplementary Video 2. Laryngeal response to mechanical insufflation–exsufflation (MI-E) 
in a healthy control visualised in real-time and slow motion by video-recorded transnasal 
fibreoptic laryngoscopy. 
Supplementary Video 3. Laryngeal response to mechanical insufflation-exsufflation (MI–E) 
in a patient with progressive bulbar ALS visualised in real-time and slow motion by video-
recorded transnasal fibreoptic laryngoscopy. 
Supplementary Video 4. Laryngeal response to mechanical insufflation–exsufflation (MI-E) 
in a patient with pseudobulbar ALS visualised in real-time and in slow motion by video-
recorded transnasal fibreoptic laryngoscopy. 
Supplementary Tables 
Supplementary Table S1. Standardised protocol of conditions during intervention with MI-E and MI  
Intervention  
arm 
Pressure settings (cmH2O):  Instruction during exsufflation: Manual thoracic 
thrust MI-E MI active exhale active cough 
1. ±20  ×   
2. ±20   ×  
3.  +20  × × 
4. ±30  ×   
5. ±30   ×  
6.  +30  × × 
7. ±40  ×   
8. ±40   ×  
9.  +40  × × 
10. ±50  ×   
11. ±50   ×  
12.  +50  × × 
MI-E=mechanical insufflation–exsufflation, MI=mechanical insufflation. Intervention arms 1–12: 
respective pressures of MI-E or MI combined with instruction to either exhale actively or to cough during 
exsufflation. Additional manual thoracic thrust during cough was provided in combination with MI.  
 
  
Supplementary Table S4. Laryngeal response patterns during mechanical insufflation according to applied 
pressures. P-values are from comparisons between the ALS group and the control group, between the 
control group and the ALS group with bulbar symptoms, and between ALS without and with bulbar 
symptoms. 
DURING INSUFFLATION 
MI-E pressures (cmH2O) ±20 ±30 ±40 ±50 
Comparisons between ALS patient group (n=20) and healthy control group 
(n=20) 
A. Initial abduction of TVF n.s. n.s. n.s. n.s. 
B. Subsequent adduction of TVF .003 .03 .002 .003 
C. Initial abduction of AEF .003 .003 .002 .008 
D. Adduction of AEF .003 .04 .02 .002 
E. Retroflex movement of EG n.s. n.s. n.s. n.s. 
F. Backward movement of BT .003 .006 <.001 <.001 
Comparisons between healthy (n=20) vs ALS with bulbar symptoms (n=14) 
A. Initial abduction of TVF n.s. n.s. n.s. n.s. 
B. Subsequent adduction of TVF n.s. n.s. n.s. n.s. 
C. Initial abduction of AEF n.s. n.s. n.s. n.s. 
D. Adduction of AEF n.s. n.s. n.s. .02 
E. Retroflex movement of EG n.s. n.s. n.s. n.s. 
F. Backward movement of BT n.s. n.s. n.s. .02 
Comparisons between ALS without bulbar symptoms (n=6) vs ALS with 
bulbar symptoms (n=14) 
A. Initial abduction of TVF n.s. n.s. n.s. n.s. 
B. Subsequent adduction of TVF n.s. n.s. n.s. n.s. 
C. Initial abduction of AEF n.s. n.s. .03 n.s. 
D. Adduction of AEF n.s. n.s. n.s. .02 
E. Retroflex movement of EG n.s. n.s. n.s. n.s. 
F. Backward movement of BT n.s. n.s. n.s. n.s. 
Comparisons between pseudobulbar ALS (n=7) vs progressive bulbar ALS 
(n=7) 
A. Initial abduction of TVF n.s. n.s. n.s. n.s. 
B. Subsequent adduction of TVF n.s. n.s. n.s. n.s. 
C. Initial abduction of AEF n.s. n.s. n.s. n.s. 
D. Adduction of AEF n.s. n.s. n.s. n.s. 
E. Retroflex movement of EG n.s. n.s. n.s. n.s. 
F. Backward movement of BT n.s. n.s. n.s. n.s. 
P-values were calculated using the chi-square test or Fisher’s exact test if expected cell counts were less 
than five. MI-E=mechanical insufflation–exsufflation, TVF=true vocal folds, AEF= aryepiglottic folds, 
EG=epiglottis, BT=base of the tongue, n.s.=non-significant 
  
Supplementary Table S5. Laryngeal response patterns during the pressure drop according to applied 
pressures and instructions. P-values are from comparisons between the ALS group and the control group, 
between the control group and the ALS group with bulbar symptoms, and between ALS without and with 
bulbar symptoms. 
DURING THE PRESSURE DROP 
Instruction during exsufflation: Cough Exhale 
MI-E pressures (cmH2O) ±20  ±30  ±40  ±50  ±20  ±30  ±40  ±50  
Comparisons between ALS patient group (n=20) and healthy control group (n=20) 
G. Adduction of TVF  n.s. n.s. .04 n.s. n.s. n.s. n.s. n.s. 
H. Adduction of AEF  n.s. n.s. n.s. n.s. n.s. .01 n.s. n.s. 
I. Abduction of TVF n.s. n.s. n.s. n.s. .008 n.s. n.s. n.s. 
J. Abduction of AEF n.s. n.s. n.s. n.s. .008 n.s. n.s. n.s. 
K. Retroflex movement of EG n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
L. Backward movement of BT .048 .001 .002 <.001 n.s. .002 .008 <.001 
Comparisons between healthy (n=20) and ALS with bulbar symptoms (n=14) 
G. Adduction of TVF  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
H. Adduction of AEF  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
I. Abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
J. Abduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
K. Retroflex movement of EG n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
L. Backward movement of BT n.s. .02 .02 .02 n.s. n.s. n.s. <.001 
Comparisons between ALS without bulbar symptoms (n=6) vs ALS with bulbar symptoms (n=14) 
G. Adduction of TVF  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
H. Adduction of AEF  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
I. Abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
J. Abduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
K. Retroflex movement of EG n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
L. Backward movement of BT n.s. n.s. n.s. .03 n.s. n.s. n.s. n.s. 
Comparisons between pseudobulbar ALS (n=7) vs progressive bulbar ALS (n=7) 
G. Adduction of TVF  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
H. Adduction of AEF  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
I. Abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
J. Abduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
K. Retroflex movement of EG n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
L. Backward movement of BT n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
P-values were calculated using the chi-square test or Fisher’s exact test if expected cell counts were less 
than five. MI-E=mechanical insufflation–exsufflation, TVF=true vocal folds, AEF=aryepiglottic folds, 
EG=epiglottis, BT=base of the tongue, n.s.=non-significant 
 
Supplementary Table S6. Laryngeal response patterns during mechanical exsufflation according to applied 
pressures and instructions. P-values are from comparisons between the ALS group and the control group, 





Cough Exhale Cough with no 
exsufflation 
MI-E pressures (cmH2O) ±20  ±30  ±40  ±50  ±20  ±30  ±40  ±50  +20 +30 +40 +50 
Comparisons between ALS patient group (n=20) and healthy control group (n=20) 
M. Initial abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
N. Subsequent adduction of TVF <.001 .001 <.001 <.001 .001 .003 .02 .005 .003 .001 .007 <.001 
O. Initial abduction of AEF n.s. .003 .005 .005 .008 .003 .002 .001 .008 .02 .001 .002 
P. Subsequent adduction of AEF n.s. .048 n.s. n.s. .016 .002 .02 .005 n.s. n.s. n.s. n.s. 
Q. Retroflex movement of EG  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
R. Hypopharyngeal constriction .03 n.s. n.s. n.s. n.s. n.s. .02 n.s. .010 n.s. n.s. n.s. 
S. Repetitive glottic closures n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Comparisons between healthy (n=20) and ALS with bulbar symptoms (n=14) 
M. Initial abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
N. Subsequent adduction of TVF .03 .004 .002 .002 .03 n.s. n.s. n.s. .03 .009 .05 <.001 
O. Initial abduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
P. Subsequent adduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Q. Retroflex movement of EG  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
R. Hypopharyngeal constriction n.s. n.s. n.s. n.s. n.s. .008 .007 n.s. n.s. n.s. n.s. n.s. 
S. Repetitive glottic closures n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Comparisons between ALS without bulbar symptoms (n=6) vs ALS with bulbar symptoms (n=14) 
M. Initial abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
N. Subsequent adduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
O. Initial abduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. .02 
P. Subsequent adduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Q. Retroflex movement of EG  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
R. Hypopharyngeal constriction n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. .01 n.s. 
S. Repetitive glottic closures n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Comparisons between pseudobulbar ALS (n=7) vs progressive bulbar ALS (n=7) 
M. Initial abduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
N. Subsequent adduction of TVF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
O. Initial abduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
P. Subsequent adduction of AEF n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Q. Retroflex movement of EG  n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
R. Hypopharyngeal constriction n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
S. Repetitive glottic closures n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
P-values were calculated using the chi-square test or Fisher’s exact test if expected cell counts were less 
than five. MI-E=mechanical insufflation–exsufflation, TVF=true vocal folds, AEF=aryepiglottic folds, 
EG=epiglottis, BT=base of the tongue, n.s.=non-significant 
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